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MY  PERSONAL  VIEW  OF  THE  IMMUNE  SYSTEM  
The  few  of  you  that  might  have  visited  my  hometown,  Xi’an  (China),  must  have  been  
impressed  by  the  spectacular  scene  of  the  ‘Terracotta  Army’.  However,  as  a  local  kid  
breathing  the  city’s  air,  my  favorite  has  always  been  the  rectangular-­shaped  city  walls,  
which  has  been  offering  security  to  the  inner  city  for  more  than  600  years*.    
Not  until  when  I  have  learned  more  about  the  immune  system,  I  started  to  realize  how  
perfectly  the  structure  of  ancient  Xi’an  city  could  explain  the  sophisticated  design  of  
the   human   body.   The   walls,   just   like   the   skins,   frequently   reject   life-­threatening  
invading   enemies   (microbes   and   viruses).  Within   these  walls,   vital   facilities   (brain,  
heart,  lungs  etc.)  and  civilians  (normal  tissues)  could  function  well  under  the  protection  
of  the  highly-­skilled  watchmen  of  the  city  (immune  system).    
In  general,  this  protecting  force  comprises  of  military  troops  that  have  large  numbers  
of  soldiers  (T  and  B  lymphocytes)  as  well  as  specialized,  fast-­responding  fighters  (NK  
cells)  and  special  agents  (myeloid  cells).  Once  there  is  a  break-­in  at  any  point  of  the  
fortification,   guards   will   light   up   the   beacon   tower   (inflammation)   and   the   special  
agents  will  be  summoned  immediately.  They  could  release  explosive  weapons  to  kill  
the   invaders  and   report   first-­hand   information   to   initiate  military  operations   later  on  
(antigen  presentation).  
In  comparison  to  microbes  and  viruses,  cancer  initiation  is  more  similar  to  a  gangster  
group  started  within  the  city.  In  most  cases,  this  kind  of  activity  is  quickly  detected  by  
the  watchmen  and  terminated  on  the  spot.  However,  gangster  groups  could  use  many  
tricks,   for  example   fake   identities  or  acting  undercover,   to  avoid  being   recognized.  
When   these  groups  have  gained  enough  power,   they  could  even  corrupt   the  city’s  
watchmen  and  receive  assistance  to  spread  their  influences  to  other  functioning  parts  
(metastasis).    
The  special  agents,  myeloid  cells  as  we  mentioned  earlier,  normally  are  among  the  
first  ones  to  notice  the  gangster  activities.  Part  of  their  job  is  to  gather  intelligence  by  
infiltrating   these  outlawed  groups  and  collect  key   information   that  enables  effective  
military  executions.  However,  due  to  their  constant  presence  in  the  gangs,  they  often  
betray   their   duties   and   participate   in   illegal   activities   that   support   growth   of   the  
gangster  groups.    
Investigations   conducted   in   this   thesis   focus   on   clarifying   main   channels   that   the  
gangster  groups  (tumors)  employ  to  convert  these  special  agents  (Study  I,  II  and  IV).  
In  detail,  I  aim  to  understand  how  these  converted  members  of  the  immune  system  
could   slow   down   efficient   cancer   clearance   (Study   I   and   II)   and   block   smooth  
information  transfer  to  the  authorities  (Study  III).    
The  goal  of  these  investigations  is  to  develop  counteractive  tactics  that  could  regain  
the  loyalty  of  these  ‘double-­agents’  and  ultimately  work  from  both  ends  to  efficiently  






*:   The   city  walls   in   Xi’an   are   the  most  well-­preserved   city   fortification   among   all   Chinese   cities.   Its  
construction  started  in  194  B.C.  and  the  existing  part  was  built  by  the  Ming  Dynasty  in  1370.  Nowadays  




Cancer   progression   is   often   accompanied   by   chronic   inflammation   and   severe  
impairment  of  the  immune  system.  In  recent  years,  therapies  eliciting  tumor-­specific  
immunity   have   resulted   in   striking   tumor   control   and   survival   benefits   in   cancer  
patients.   However,   establishment   of   effective   and   durable   immune   responses   is  
hampered  by  various  tumor-­dependent  mechanisms.  Besides  the  direct  suppression  
mediated  by  tumor  cells,  a  number  of  immune  cell  types,  including  regulatory  T  cells  
(Tregs),   myeloid-­derived   suppressor   cells   (MDSCs),   ‘M2-­biased’   tumor-­associated  
macrophages  (TAMs)  and  regulatory  dendritic  cells,  occur  in  the  periphery  and  tumor  
microenvironment.  These  cells  conduct  potent  inhibition  of  anti-­tumor  immunity  and  
are  associated  with  poor  prognosis  in  patients.  Studies  included  in  this  thesis  aim  to  
elucidate   the   molecular   machinery   that   tumor   cells   utilize   to   induce   suppressive  
functions   from   healthy   myeloid   cells   (Study   I,   II   and   IV)   and   how   the   resulted  
suppressive  myeloid  cells  could  limit  functions  of  T  cells  (Study  I),  natural  killer  (NK)  
cells   (Study   II)   and   differentiation   of   the   immune-­stimulating   dendritic   cells   (DCs)  
(Study   III).   Finally,   we   tested   the   role   of   a   myeloid-­specific   chemical   inhibitor   in  
antagonizing  the  induction  of  these  suppressive  myeloid  cells  in  vitro.  In  a  transgenic  
murine  model  developing  highly  aggressive  spontaneous  tumors,  treatment  with  the  
inhibitor  elicited  robust  control  of  established  tumors  and  potentiated  the  anti-­tumor  
effects  of  checkpoint  blocking  antibodies  (Study  IV).  In  summary,  this  thesis  provides  
mechanistic  insights  for  the  induction  of  suppressive  myeloid  cells  and  demonstrates  
the  therapeutic  potential  of  targeting  these  cells  for  the  treatment  of  solid  tumors.    
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GM-­CSF   Granulocyte-­macrophage  colony-­stimulating  factor  
HIF-­1α   Hypoxia  induced  factor-­1  alpha  
HMGB-­1   High-­mobility  group  box  protein  B-­1  
IDO   Indoleamine  2,3-­deoxygenase  
JAK   Janus  Kinase  
M-­CSF   Macrophage  colony-­stimulating  factor  
MDSCs   Myeloid-­derived  suppressor  cells  
MHC   Major  histocompatibility  complex  
mPGES-­1   Membrane-­associated  PGE  synthase-­1  
NKG2D   Natural-­killer  group  2,  member  D  
NOS   Nitric  oxide  synthase  
PBMC   Peripheral  blood  mononuclear  cells  
PD-­1   Programmed  cell  death-­1  
PDE-­5   Phosphodiesterase  type-­5  
PDGF   Platelet-­derived  growth  factor  
PD-­L1  or  -­L2   Programmed  cell  death  ligand-­1  or  -­2  
  
PGE2   Prostaglandin  E2  
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RAGE   Receptor  for  advanced  glycation  endproducts  
RNS   Reactive  nitrogen  species  
ROS   Reactive  oxygen  species  
ScFv   Single-­chain  variable  fragment  
STAT   Signal  transduction  and  transcription  
TAA   Tumor-­associated  antigen  
TAM   Tumor-­associated  macrophages  
TGF-­β   Transforming  growth  factor-­beta  
TLR   Toll-­like  receptor  
TRAIL   TNF-­related  apoptosis-­inducing  ligand  
Treg   Regulatory  T  cells  
VEGF   Vascular  endothelial  growth  factor  
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FOREWORD  
Since  the  beginning  of  my  scientific  training  in  2009,  I  have  frequently  heard  the  strong  
doubts   about   cancer   immunotherapy   just   a   few   years   ago.   One   of   the   common  
arguments  that  discredited  the  ability  of  the  immune  system  in  controlling  established  
tumors  was  based  on  observations  that  tumors  continued  to  progress  despite  being  
‘surrounded’  by  immune  cells.  In  the  clinic,  boosters  for  the  immune  system,  such  as  
interleukin-­2  (IL-­2)  or  interferon-­γ  (IFN-­γ),  caused  severe  systemic  adverse  events  but  
only  showed  therapeutic  effects  in  a  small  number  of  patients.  On  the  other  hand,  less  
toxic  approaches,  such  as  cancer  vaccines,  struggled  to  achieve  satisfactory  clinical  
responses  against  established  solid  tumors.    
Recently,   success   stories   of   the   uprising   immunotherapies,   such   as   ‘check-­point’  
blocking  antibodies  and  various  adoptive  cell  transfer  strategies,  have  energized  the  
research  in  cancer  immunology  once  again.  Massive  eradication  and  durable  tumor  
control   have   been   documented   in   patients  who   have   failed   to   respond   to   existing  
treatments.  More  importantly,  these  new  approaches  have  ‘revived’  an  array  of  classic  
anti-­cancer   drugs,   to   be   tested   at   lower   doses   as   part   of   the   combinational  
approaches.    
However,  for  anti-­tumor  immunity  to  operate  optimally  in  a  larger  number  of  patients,  
we  cannot  avoid  challenges  from  the  extremely  hostile  environment  in  cancer  patients.  
Some  argue  that  this  problem  could  be  sufficiently  overcome  once  dominant  strength  
of  the  immune  responses  are  introduced,  for  example  by  pumping  in  trillions  of  tumor-­
reactive   T   cells.   This   option   is   potentially   risky   due   to   collateral   damages   against  
healthy   tissues   caused   by   this   ‘unleashed’   T   cell   army.   Thus,   it   is   reasonable   to  
hypothesize   that   we   may   achieve   a   ‘1+1>2’   situation,   when   immune-­activating  
reagents   are   wisely   combined   with   approaches   that   disarm   resilient   mechanisms  
utilized  by  tumor  cells,  such  as  abnormal  vasculature,  immune  suppression,  hypoxia  
or  acidity.          
The  immune  system  is  a  vastly  complicated  network  involving  many  distinct  cell  types.  
Therefore,   we   are   still   in   great   needs   of   in-­depth   knowledge   on   how   the   immune  
system  functions  in  cancer  patients,  for  example  how  immune  cells  could  interact  with  
tumor  cells  and  regulate  each  other.  Identification  of  these  ‘missing  pieces’,  facilitated  
by   refined   technological  advances,  could  help  us   identify  new   targets  and  develop  
approaches  that  could  not  only  generate  sufficient  clinical  efficacy,  but  also  improve  
the  quality-­of-­life  for  cancer  patients.     
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1.  SNAPSHOTS  OF  THE  IMMUNE  SYSTEM  
1.1  INTRODUCTION  
The  textbook  model  divides  the  immune  system  into  innate  and  adaptive  arms.  The  
former  includes  a  variety  of  cell  types  that  quickly  respond  to  invading  pathogens.  In  
contrast,  the  latter  refers  to  responses  directed  by  selected  fragments  of  pathogens  
and   is   thought   to  be  the  exclusive  effectors  for   the  establishment  of   immunological  
memory.  However,  as  emerging  evidence  points  towards  the  memory  properties  of  
certain  innate  immune  subsets  [1],  it  is  becoming  increasingly  challenging  to  utilize  the  
classic   definitions   to   address   current   immunological   questions.   Thus,   instead   of  
categorizing   immune   cell   subsets   following   the   framework,   I  will   try   to   explain   the  
immune  response  as  a  process  and  introduce  key  elements  involved  in  every  major  
step.    
1.2  THE  FAST-­RESPONDING  IMMUNITY  
The  principle  of  immune  protection  is  largely  based  on  the  ’danger  signal  hypothesis’,  
which  was   a   concept   first   suggested   by  Burnet   in   1949   and   refined   by   numerous  
subsequent   studies   [2].   In   simple   words,   the   evolutionary   force   has   shaped   the  
immune  system  to  detect  common  features  of  dangerous  pathogens,  known  as  the  
pathogen-­associated  molecular  patterns   (PAMPs).  Once  healthy  cells  are   infected,  
they   will   express   the   ‘kill-­me’   signals,   or   damage-­associated   molecular   patterns  
(DAMPs),  in  order  to  initiate  immune  recognitions.  A  group  of  immune  cells,  known  as  
the  antigen-­presenting  cells  (APCs),  bear  receptors  that  specifically  bind  to  PAMPs  or  
DAMPs.  Upon  detection  of  PAMPs  or  DAMPs,  APCs  can  capture  the  infected  cells  
and  extract  antigens,  which  are  small  peptide  fragments  that  are  essential  for  eliciting  
further   immune   responses.   Generally,   this   process   initiates   within   hours   after  
infections  and  the  antigen-­carrying  APCs  will  migrate  to  lymph  nodes  and  activate  the  
residing  T  and  B  lymphocytes.  We  will  have  a  closer  look  at  this  process  in  the  sections  
below.  
Besides  APCs,  other   immune  cells  are  also  playing  pivotal   roles   in   the   immediate  
control   of   invading   pathogens.   NK   cells   constitute   approximately   5   to   15%   of   the  
immune  cells   in  human  peripheral  blood  and   rapidly   respond   to  cells   lacking  MHC  
class  I  surface  molecules,  which   is  often  caused  by  viral   infections  [3,  4].  Previous  
studies  have  revealed  that  development  and  effector  functions  of  NK  cells  are  fine-­
tuned  by  a  panel  of  inhibitory  and  activating  molecules  [5].  Recently,  a  hotly  debated  
topic  underlines  the  memory  property  of  NK  cells  in  an  antigen-­specific  manner  [6-­9],  
which  is  traditionally  considered  to  be  exclusive  for  secondary  immune  effector  cells  
[10].  Moreover,  the  complement  system,  which  comprises  a  multitude  of  circulating  or  
membrane-­associated  proteins  with  enzymatic  activities,  plays  a  rapid  defensive  role  
through  lysis  of  microbes.  In  many  cases,  the  fast-­responding  immunity  is  not  sufficient  
to  eradicate  invading  pathogens.  Therefore,  secondary  immunity,  which  takes  a  few  
days  to  reach  its  maximal  capacity,  needs  to  be  recruited.  
1.3  THE  THREE  SIGNALS  
1.3.1  Antigen  presentation  to  T  lymphocytes  
T   cell   receptors   (TCRs)   are   unique   surface   molecules   that   are   essential   for   the  
activation  and  functions  of  T  lymphocytes.  Every  TCR  has  a  specific  reactivity  towards  
a  short  peptide  sequence,  which  is  presented  by  MHC  molecules  on  the  cell  surface.  
Ligation   between   peptide-­containing   MHCs   on   APCs   and   TCRs   can   induce  
intracellular  signal  transduction  cascades,  which  are  required  for  the  activation  and  
expansion  of  T  cells.  There  are  two  types  of  MHCs  involved  in  the  antigen  recognition,  
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MHC  class  I  and  II.  TCRs  on  CD8+  cytotoxic  T  cells  (CTLs)  binds  to  MHC  class  I-­
peptide  complexes,  whereas  MHC  class  II-­peptide  complexes  are  responsible  for  the  
activation  of  CD4+  helper  T  cells.    
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1.3.2  Co-­stimulation  
For   T   cells   to   reach   the   full   activation   capacity,   it   is   necessary   to   engage   signal  
transduction   mediated   by   co-­stimulatory   molecules   on   professional   APCs.  
Represented  by  the  B7  family  members,  for  example  B7.1  (CD80)  and  B7.2  (CD86),  
these  molecules  could  bind  to  various  receptors  such  as  CD28  on  T  cells.  This  ligation  
induces  vital  signals  for  the  survival  and  expansion  of  T  cells.  In  addition,  together  with  
other  adhesion  molecules,  binding  to  co-­stimulatory  molecules  could  enhance  T  cell  
activation  by  stabilizing  immune  synapses  between  APCs  and  T  cells.  As  opposed  to  
the   co-­stimulatory   molecules,   there   are   also   co-­inhibitory   molecules   that   function  
through  similar  principles  but  negatively  regulate  T  cells  functions.  This  mechanism  is  
essential  to  maintain  immune  homeostasis  after  infections  and  forms  a  major  barrier  
for  tumor-­reactive  immune  responses.  I  will  mention  this  pathway  and  its  therapeutic  
potential  for  cancer  treatment  in  later  sections.  
1.3.3  Cytokines  
Cytokines  are  proteins  that  regulate  cell  functions  through  binding  to  their  matching  
receptors.  APCs  can  release  a  panel  of  cytokines  that  potentiate  various  functions  of  
T   cells.   For   example,   IL-­12   produced   by   APCs   during   antigen   presentation   could  
stimulate  production  of  IFN-­γ  from  T  cells,  which  is  a  key  regulator  for  immune  defense  
[11].  Moreover,   cytokine  environment   during  antigen  presentation   could   shape   the  
functions  of  activated  T  cells,  especially  in  the  CD4+  subset.    
1.4  THE  SECONDARY  IMMUNITY  
1.4.1  T  lymphocytes  
As   a   result   of   the   three   signals,   large   numbers   of   pathogen-­reactive   T   cells   are  
produced  through  clonal  expansion.  These  cells  will  then  migrate  to  the  infection  sites  
and  eliminate  invading  pathogens  or  infected  host  cells.  CD8+  CTLs  recognize  cells  
presenting  peptides  by  the  MHC  class  I  molecules  and  induce  apoptosis  of  target  cells  
through   a   variety   of   mechanisms,   including   perforin,   granzymes,   granulysin   or  
membrane-­bound  molecules  such  as  FasL  or  TRAIL.  On  the  other  hand,  the  classic  
model  describes  CD4+  T  cells  to  function  mainly  by  producing  cytokines.  Based  on  
the  cytokines  that  activate  them  and  those  released  by  these  CD4+  T  cells,  they  can  
be  categorized  into  the  Th1  or  Th2  subsets.  Th1  cytokines,  such  as  IFN-­γ,  IL-­2  and  
TNF-­α,  promote  immune  functions  of  CTLs,  macrophages  or  NK  cells.  In  contrast,  Th2  
cells  produce  distinct  cytokines,  for  example  TGF-­β,  IL-­10  and  IL-­4,  and  are  thought  
to  mainly  regulate  humoral  immune  responses.  The  balance  between  Th1  and  Th2  
cells  has  been  proposed  to  be  critical  in  autoimmunity,  allergy  and  cancer.  
1.4.2  Humoral  responses  
Humoral  responses  are  featured  by  the  activation  of  B  lymphocytes  and  production  of  
antibodies.  B  cell  receptors  (BCRs)  are  membrane-­bound  immunoglobulins  (IgG)  that  
recognize   specific   antigens.   Thus,   different   from   TCRs,   BCR   signaling   does   not  
require   the   presence   of   MHC-­peptide   complexes.   Instead,   BCRs   could   directly  
recognize  microbial  surfaces.  Consequently,  this  recognition  will  result  in  proliferation  
of  B  cells  with  pathogen-­specific  BCRs  and  promote  their  maturation  into  antibody-­
producing   plasma   cells.   This   process   will   lead   to   increased   concentrations   of  
antibodies  which  will  bind  to  the  pathogens  and  result  in  clearance  through  antibody-­
mediated  cellular  cytotoxicity  (ADCC).  In  addition,  B  cells  are  equipped  with  MHC  and  
co-­stimulatory  machinery  and  could  activate  and  amplify  antigen-­specific  T  cells.     
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2.  IMMUNE  RESPONSES  IN  CONTROLLING  CANCERS  
2.1  HISTORICAL  OVERVIEW  
In  1909,  Enrlich  proposed  that  immune  surveillance  was  engaged  in  the  eradication  
of  transformed  cells  [12]  and  this  hypothesis  was  elaborated  by  Burnet  a  few  decades  
later  [13,  14].  However,  several  lines  of  experimental  evidence  argued  that  immune  
surveillance  was  not  involved  in  limiting  spontaneous  or  chemically  induced  tumors  
because  tumor  growth  was  comparable  between  immunodeficient  athymic  nude  mice  
and  wild-­type  controls    [15-­18].  It  was  later  shown  that  the  development  of  NK  cells,  
γδ-­T  cells  and  some  subsets  of  T  cells  were  still  present  in  athymic  nude  mice  [19,  
20].   In   addition,   wild-­type   mice   indeed   demonstrated   substantially   lower   tumor  
incidence  when  the  chemical  carcinogen  dosage  was  carefully   titrated  [21].  Similar  
results  were  obtained  from  RAG-­2-­deficient  mice  [22]  that  lack  functional  B  and  T  cell  
populations   [18,   23].   More   recently,   animal   models   created   by   gene-­targeting  
technologies  allowed  mechanistic  analysis  of  immunological  pathways  in  controlling  
tumor  development,  including  TCR  signaling  of  T,  NKT  or  γδ-­T  cells  [24-­26],  synthesis  
of  type  I  IFNs  [27-­29]  and  perforin  [26,  30].  On  the  other  hand,  tumor  progression  is  
often   accompanied   by   a   panel   of   mechanisms   that   hamper   effective   clearance  
mediated   by   the   immune   system   (section   2.2).   Collectively,   these   observations  
delineated  the  dynamic  dialogues  between  tumor  cells  and  the  immune  system  during  
cancer  occurrence  and  development  [31,  32].      
2.2  BARRICADES  FOR  ANTI-­TUMOR  IMMUNITY  
As   briefly   discussed   in   the   earlier   section,   tumor-­induced   immune   suppression  
attenuate  effective  anti-­tumor   immune   responses.  Even   though  many  different   cell  
types  mediate  these  effects,  the  molecular  basis  of  the  suppression  is  overlapping.  
Below  I  will  introduce  some  key  aspects  of  these  mechanisms.  
2.2.1  Regulatory  T  cells  
Regulatory  T  cells  (Tregs)  naturally  occur  in  the  thymus  and  are  important  to  maintain  
self-­tolerance   in   physiological   conditions   [33].   In   malignancies   and   inflammation,  
Tregs  could  be  induced  in  response  to  various  inflammatory  signals,  such  as  IL-­10,  
TGF-­β  and  PGE2  [34].  Tregs  belong  to  the  CD4+  helper  T  cell  subsets  and  express  
CD25   (IL-­2Rα)   on   the   surface   and   transcriptional   factor   FoxP3   intra-­cellularly.  
Moreover,   low  expression  of  CD127  (IL-­7Rα)  was  used  to  define  Tregs   in  humans  
[35].  Numerous  in  vivo  studies  have  demonstrated  that  Tregs  form  a  substantial  barrier  
for  anti-­tumor  immune  responses.  Due  to  the  high  expression  of  CD25,  Tregs  are  able  
to  deplete  IL-­2  from  effector  T  cells,  therefore  hamper  their  activation  and  functions  
[35].  In  addition,  Tregs  are  potent  producers  for  immune-­regulatory  cytokines  such  as  
IL-­10  or  TGF-­β  [36,  37].  Further,  Tregs  could  be  more  resistant  to  apoptosis   in  the  
tumor  microenvironment   by   releasing   antioxidant   thioredoxin-­1   [38].   These   factors  
conduct   multi-­faceted   effects   and   facilitate   tumor   growth   and   metastasis.   Indeed,  
depleting  Tregs   by   low-­dose   cytoxan   potentiated   the   therapeutic   effects   of   cancer  
vaccines  in  the  HER2/neu  transgenic  mice  [39].  
2.2.2  Immune  checkpoints  
Sufficient   antigen   presentation   requires   co-­stimulatory   signals   triggered   by   APCs.  
However,  co-­inhibitory  molecules,  also  known  as  immune  checkpoints,  also  exist  in  
order   to   restore   homeostasis   after   immune   clearance   [40].      The   most   well-­
characterized  immune  checkpoint  to  date  is  CTLA-­4  [41,  42],  which  expresses  at  high  
levels  on  activated  T  cells  and  binds  to  CD80/86  with  an  affinity  that  was  superior  to  
CD28   [43],  which   is   a   T   cell-­activating   receptor   that   also   binds   to  CD80/CD86.   In  
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addition,  CTLA-­4  could  remove  CD80/86  from  APCs  through  trans-­endocytosis  [44].  
Similarly,  PD-­1  emerges  when  T  cells  are  activated  [45]  and  can  negatively  regulate  
T  cell  functions  and  induce  T  cell  apoptosis  through  ligation  to  PD-­L1  [46,  47]  or  PD-­
L2  [48,  49].  Other  co-­inhibitory  ligands  such  as  B7-­H3  and  B7-­H4  [50,  51]  were  also  
identified,   but   their   matching   receptors   on   T   cells   and   detailed   functions   remain  
elusive.  Expression  of   these   immune  checkpoints  on   tumor  or   immunosuppressive  
cells  is  known  to  be  important  protective  mechanisms  that  facilitate  tumor  growth  [52,  
53]   and   have   proven   to   be   one   of   the  most   promising   therapeutic   targets   for   the  
treatment  of  human  cancers  (section  3.1).  
2.2.3  Enzymatic  machinery  
Tumor   tissues   are   featured   by   high   levels   of   energy   consumption   and   altered  
metabolic  profile.  Thus,  production  of  various  enzymes  exhausts  crucial  amino  acids  
that  could  support  anti-­tumor  immunity.  For  example,  L-­arginine  is  extremely  important  
for  maintaining  TCR  signaling  and  T  cell  functions  [54].  Activation  of  myelomonocytic  
cells  by  tumor-­derived  factors  could  lead  to  massive  production  of  ARG  and  inducible  
NOS   (iNOS)   that   results   in  T  cell   anergy  by   rapid  depletion  of  L-­arginine   [55]  and  
release  of  NO  [56,  57].  However,  since  production  of  NO  was  shown  to  be  one  of  the  
defending  mechanisms  mediated  by  macrophages  against  cancer  cells  [58],  the  role  
of   NO   on   anti-­tumor   immunity   is   still   not   clear.   A   recent   study   showed   low-­dose  
irradiation  promoted  macrophage-­mediated  tumor  rejection  through  the  NOS  pathway  
[59].   Even   though   ARG   and   iNOS   regulate   independent   catalytic   pathways,   co-­
expression   of   these   two   enzymes   are   often   observed,   which   leads   to   challenging  
situations  for  designing  treatment  strategies.  
Another  important  enzyme  is  IDO,  which  catalyzes  tryptophan  to  N-­formyl-­kynurenine  
[60].  It  is  an  important  regulatory  channel  for  APCs  to  modulate  T  cell  functions  during  
antigen  presentation  through  calibrating  tryptophan  levels  [61,  62].  Tumor  cells  and  
many  types  of  immunosuppressive  cells  also  utilize  this  pathway  to  sabotage  T  cell  
responses  [63].  Besides  the  direct  effects,  IDO  activity  could  control  other  regulatory  
schemes  in  the  tumor  micro-­environment,  including  COX-­2/PGE2  pathway  [64,  65],  
TGF-­β  or  IL-­10  production  [66,  67].  Thus,  it  is  becoming  therapeutically  appealing  to  
target   IDO  activity  due  to  the  potential  effects  on  both  tumor  cells  and  the   immune  
system.  Certainly,  pharmacological  inhibitors  of  IDO  activity  have  demonstrated  anti-­
tumor  effects  [68]  and  boosted  chemotherapy  [69]  and  checkpoint  inhibitors  [70,  71]  
in  murine  models.    
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2.3  IMMUNOSCORE:  Creating  Immunological  Signatures  for  Cancer  Classification  
Observations  of  inflammatory  immune  cells  in  human  tumor  tissues  date  back  to  1863  
by  pathologist  Rudolf  Virchow.  Nowadays,  it  is  well-­documented  that  density  of  CD8+  
CTL   could   independently   predict   the   clinical   outcome   in   various   types   of   human  
cancers  [72-­74].  Infiltration  of  NK  cells  has  also  been  reported  to  be  a  positive  factor  
in  human  cancers  [75-­77].  In  contrary,  the  prognostic  role  of  suppressive  immune  cells  
has  been  inconsistent.  In  some  reports,   ‘M2-­biased’  macrophages  [78-­81]  or  Tregs  
[82-­84]  are  associated  with  poor  clinical  outcome  but  correlated  with  better  patient  
survival  in  other  studies  [85-­87].    
In  a  study  published  by  Galon  et  al.  [88],  a  large  quantity  of  immune-­related  genes  
were  screened  and  candidate  genes  were  validated  by  tissue  microarray  in  colorectal  
cancer  tissues.  Strikingly,  it  revealed  that  density  of  CD45RO+  memory  T  cells  in  the  
tumors   provided   an   independent   predictive   factor   that   was   complementary   to   the  
traditional  histopathological  classification  system  (Figure  1).  In  particular,  late-­stage  
tumors  crowded  with  memory  T  cells  may  have  more  favorable  survival  than  early-­
stage   patients   lacking   T   cell   infiltration   [89].   In   a   recent   study,   the   intratumoral  
‘landscape’  of  28  immune  cell  types  was  illustrated  in  colorectal  cancer  patients  and  
different  immune  cells  demonstrated  distinct  localization  in  the  tumor  [90].  Based  on  
these  findings,  Immunoscore,  which  uses  the  immune  contexture  in  human  tumors  as  
staging  criteria,  is  proposed  to  be  implemented  in  addition  to  the  TNM  classification  
method  [91,  92].  Initiated  by  a  few  researchers  focusing  on  colorectal  cancer  patients,  
it  is  to  date  a  worldwide,  multi-­center  investigation  for  various  cancer  types.  The  value  
of  Immunoscore  has  provided  solid  evidence  advocating  the  importance  of  immune  
surveillance  during  the  occurrence  and  progression  of  human  cancers.  Particularly,  
these   findings  may  have  a  profound   future   impact  on   the  diagnosis  and   treatment  
decisions  in  cancer  patients.  




Figure  1,  Cancer  classification  based  on  immune  contexture.  CT:  Center  of  the  
tumor;;  IM:  Invasive  margin;;  CD3:  T  cell  marker;;  CD45RO:  Memory  T  cell  







3.  NEW  TRENDS  IN  CANCER  IMMUNOTHERAPY  
For   decades,   immunotherapy   struggled   to   prove   its   therapeutic   efficacy   in   cancer  
patients  and  was  never  widely-­accepted  to  be  useful  as  a  treatment  option.  Nowadays,  
therapeutic  interventions  eliciting  tumor-­reactive  immunity  are  proven  to  be  clinically  
effective  even  in  patients  with  multiple  metastatic  lesions.  In  this  section,  I  will  highlight  
the   major   approaches   that   have   shown   success   in   clinical   trials.   However,   it   is  
important  to  point  out  that  this  is  an  extremely  fast-­evolving  field  that  is  powered  by  
research   talents   across   all   scientific   disciplines.   Thus,   new   treatment   concepts   or  
technical   advances  may   further   improve  our   current   view  on   this   topic   in   the  near  
future.    
3.1  ‘CHECK-­POINT’  INHIBITORS  
3.1.1  Unleashing  T  cells  by  CTLA-­4  blockade  
Immune  checkpoint  molecules  negatively  regulate  immune  effector  cells  by  binding  to  
the  matching  receptors.  As  discussed  in  section  2.2.2,  CTLA-­4  and  PD-­1  are  two  well-­
characterized   receptors   on   T   cells   and   their   therapeutic   potentials   have   been  
evaluated   in   preclinical   models   and   clinical   studies.   In   preclinical   animal   models,  
blocking  CTLA-­4  signaling  effectively  limited  tumor  growth  in  mice  through  activation  
of  T  cells  [93-­96].  Ipilimumab,  an  anti-­human  CTLA-­4  blocking  antibody,  was  approved  
by   the   FDA   in   2011   for   the   treatment   of  metastatic  melanoma   and   is   now   under  
investigation  in  patients  with  non-­small  cell  lung  carcinoma,  small  cell  lung  carcinoma,  
bladder  cancer  and  prostate  cancer.  This  approval  was  motivated  by  results  of   the  
landmark  phase  III  clinical  trial,  which  has  generated  durable  survival  advantages  in  
metastatic  melanoma  patients  who  have  failed  existing  therapies  [97-­99].  Apart  from  
attenuating   negative   signals   transduced,   blocking   antibody   for   CTLA-­4   has  
demonstrated  potent  ability  to  remove  Tregs  in  animal  models  by  ADCC  mediated  by  
immune  cells  expressing  FcγR   [100-­102].  Thus,  adjusting  Fc  binding  properties  of  
therapeutic   antibodies   according   to   the   clinical   purposes   may   boost   the   in   vivo  
efficacies  in  patients  [103].    
3.1.2  PD-­1/PD-­L  as  a  therapeutic  target  
Remarkable   clinical   responses   induced   by   ipilimumab   have   accelerated   the  
investigation  and  approval  of  blocking  antibodies  against  PD-­1  pathway.  In  melanoma  
patients,   both   nivolumab   (Bristol-­Myers   Squibb)   and   pembrolizumab   (Merck)  
generated  durable  survival  benefits  [104,  105].  As  a  result,  FDA  granted  permissions  
to  these  antibodies  for  treating  human  melanoma  recently.  Notably,  clinical  outcome  
after   ipilimumab  treatment  did  not  appear   to  predict   the  efficacy  of  PD-­1  blockade,  
since   nivolumab   enabled   substantial   clinical   responses   in   patients   who   failed   to  
respond   to   prior   ipilimumab   treatment   [106-­108].   Importantly,   sequential   but   not  
concurrent   administration  of   the   two  antibodies  appeared   to   be   clinically   favorable  
because  the  latter  resulted  in  severe  immune-­related  adverse  events  [109].  This  could  
be  explained  by  the  distinct  regulatory  role  of  PD-­1  and  CTLA-­4  on  the  immune  system  
[110].   Specifically,   mice   lacking   PD-­1   protein   experienced   tolerable   autoimmune  
reactions  [111,  112],  but  CTLA-­4  deficiency  resulted  in  devastating  autoimmunity  [113,  
114].   Thus,   it   has   been   postulated   that   PD-­1   functions   through   fine-­tuning   the  
threshold  of  T  cell   priming,  whereas   interfering  CTLA-­4  signaling   leads   to  a  broad  
activation  of  non-­specific  T  cells.  Even  though  ADCC-­mediated  removal  of  Tregs  could  
contribute  to  the  effects  of  CTLA-­4  blockade,  it  remains  to  be  clarified  whether  similar  
mechanisms  are  involved  in  PD-­1  blocking  agents.      
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Further  therapeutic  opportunities  lay  within  PD-­1  ligands  PD-­L1  and  PD-­L2,  which  are  
often  expressed  on  tumor  cells  or  immunosuppressive  cell  types.  Results  from  several  
clinical   trials   revealed   that   PD-­L1   blocking   antibody   was   well-­tolerated   and   led   to  
promising  clinical  responses  in  patients  with  various  solid  cancers  [115-­117].  Existing  
evidence   indicated   that   expression   of  PD-­L1   in   tumor   tissues   could   be   used   as   a  
predictive  marker  for  the  check-­point  blocking  antibody  treatment  [118].  Nonetheless,  
it  should  be  noted  that  this  observation  remains  controversial  since  PD-­L1  expression  
is  not  exclusive  to  tumor  cells,  but  could  also  be  expressed  by  fibroblasts,  endothelial  
cells   and   immune   cells.  Expression  of  PD-­L1   could   also  be   controlled  by  external  
factors  such  as  IFN-­γ  [119,  120],  which  is  a  cytokine  produced  by  activated  tumor-­
infiltrating   lymphocytes   (TILs)   [71,   121].   Thus,   expression   of   PD-­L1   might   be  
dynamically  regulated  by  different   treatment  strategies  or  pathological  conditions   in  
patients.    
Expression  of  PD-­L2  was  initially  identified  on  APCs  but  was  later  demonstrated  to  be  
inducible  on  immune  or  non-­immune  cell  types  by  a  range  of  soluble  factors  [49,  122,  
123].   It   is  well-­documented   to  be  a  second   ligand   for  PD-­1  and   transmits  negative  
signals  to  T  cells.  Paradoxically,  previous  findings  using  PD-­L2-­deficient  animals  or  
blocking  antibodies  have  implied  the  activating  role  of  PD-­L2  on  the  immune  system  
[52,  124,  125].  In  preclinical  tumor  models,  most  results  available  to  date  included  PD-­
L2  blockade  as  an  addition  to  the  anti-­PD-­1/PD-­L1  antibodies  [126,  127].  Even  though  
blocking   PD-­L2   indeed   enhanced   anti-­tumor   effects   of   other   check-­point   blocking  
agents  [128],  PD-­L2  knock-­out  mice  conversely  demonstrated  more  aggressive  tumor  
progression  [129].  Due  to  its  unclear  biological  functions,  clinical  approaches  towards  
PD-­L2  are  currently  scarce.  In  a  recently  completed  phase  I  study  (NCT01352884),  a  
PD-­L2-­IgG1   fusion   protein   was   well   tolerated   and   induced   promising   clinical  
responses  in  advanced  cancers  (abstract  3044,  2013  ASCO  meeting).  Nonetheless,  
it  is  yet  to  be  revealed  in  a  larger  cohort  of  patients  how  this  agent  could  potentiate  
anti-­tumor  immunity.  
In  order  to  achieve  thorough  blockade  of  the  PD-­1  pathway,  it  might  be  of  necessity  
to  combine  anti-­PD-­1  and  anti-­PD-­L1  approaches.  On  one  hand,  both  PD-­L1  and  PD-­
L2  could  diminish  T  cell  activation  through  PD-­1  signaling.  On  the  other  hand,  PD-­L1  
was   shown   to   inhibit   proliferation   and   expansion   of   PD-­1-­deficient   T   cells   [43],  
indicating  multiple  receptors  could  be  coupled  to  PD-­L1.  
In   summary,   immune   check-­point   blockers   have   generated   encouraging   clinical  
responses  and  elicited  durable  tumor  control  in  patients  with  advanced  solid  tumors.  
However,  current  clinical  trials  are  predominantly  focusing  on  melanoma  or  smoking-­
related  lung  cancers,  which  are  believed  to  be  more  immunogenic  due  to  their  high  
mutation  rates.  Thus,  clinical  efficacy  of  these  agents  in  other  cancer  types  remains  to  
be  explored.  Taken  into  account  that  CTLA-­4  and  PD-­1  are  two  of  the  many  members  
in   the   immune   check-­point   family,   novel   targets  may   emerge   as   the   fundamental  
mechanistic  landscape  of  these  proteins  is  depicted.    
3.1.3  Unique  clinical  properties  of  check-­point  inhibitors  
Currently,  clinical  efficacy  of  anti-­cancer  treatments  is  mainly  evaluated  according  to  
the  Response  Evaluation  Criteria  in  Solid  Tumors  (RECIST)  criteria,  which  measure  
decrease  of   tumor   volumes  after   drug   administration.  However,   immune-­activating  
agents   have   demonstrated   very   unique   response   patterns   in   cancer   patients.   In  
certain  cases,  enlargement  of  tumor  lesions  or  appearance  of  new  lesions  have  been  
documented  before   the  onset  of  a   late  clinical   response  after   ipilimumab  treatment  
[130,  131].  This  could  be  explained  by  the  distinct  kinetics  for  establishing  effective  
immune  responses  and   infiltration  of   immune  cells   into   tumor   tissues  may  result   in  
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increased  tumor  volumes.  Therefore,  it   is  critical  to  adjust  the  evaluation  criteria  for  
cancer  immunotherapy.  
Recent  clinical  experiences  with  ipilimumab  revealed  that  check-­point  inhibitors  may  
induce  severe  immune-­related  adverse  events  in  cancer  patients  [132,  133].  This  is  a  
direct  indicator  for  the  potency  of  these  agents  in  activating  the  immune  system,  but  it  
also   has   posed   challenges   for   clinical   care   of   the   patients.   Emerging   results  
demonstrated  that  blocking  PD-­1  or  PD-­L1  was  associated  with  more  tolerable  toxicity.  
It  is  in  line  with  the  magnitude  of  autoimmunity  observed  in  animals  lacking  CTLA-­4  or  
PD-­1  expressions.  Consequently,   in-­depth  knowledge  of   the  biological   functions  of  
immune   check-­point   pathways   may   be   of   essential   for   the   development   of   novel  
immunotherapeutics.  
3.2  ADOPTIVE  CELL  TRANSFER  
Given  that  immune  responses  are  capable  of  controlling  tumor  growth,  it  is  reasonable  
to  hypothesize  that  adoptive  infusion  of  highly  functional  tumor-­reactive  immune  cells  
could  be  effective  as  a   therapeutic  approach.  Numerous   investigations  have  been  
conducted  and  many  have  shown  stunning  anti-­tumor  effects.   In   this  section,   I  will  
briefly  summarize  treatment  strategies  utilizing  activated  T  cells  or  NK  cells  in  human  
solid  and  hematological  malignancies.    
3.2.1  Tumor-­infiltrating  lymphocytes  (TILs)  
Solid  tumor  tissues  are  often  infiltrated  with  T  lymphocytes,  which  is  an  independent  
prognostic  factor  for  clinical  outcome  in  various  types  of  cancer  as  discussed  earlier.  
Moreover,  it  is  generally  believed  that  T  cells  in  tumor  tissues  are  recruited  due  to  their  
tumor-­targeting  properties.  Proven  to  be  effective  in  human  melanoma  in  1988  [134,  
135],  TILs  retrieved  from  surgically  removed  tumor  tissues  followed  by  activation  with  
high-­dose  IL-­2  have  become  an  attractive  treatment  option.  Even  though  not  validated  
in  the  original  report,  it  was  later  shown  that  ability  of  TILs  to  kill  autologous  tumor  cells  
in   vitro   could   strongly   predict   the   response   rate   in   patients   [135,   136].   Further,  
transferring   TILs   containing   both   CD4+   and   CD8+   T   cells   [137,   138],   as   well   as  
lymphodepletion   in   patients   prior   to   adoptive   T   cell   transfer   [138,   139]   were  
demonstrated  to  be  key  factors  for  clinical  efficacy.  This  could  be  due  to  clearance  of  
suppressive  Tregs  and  retention  of  available  T  cell  stimuli,  such  as  IL-­2,  IL-­7  and  IL-­
15  in  vivo.  These  findings  have  introduced  valuable  modifications  to  the  TILs  treatment  
procedures.   In  an  updated   report  containing  93  metastatic  melanoma  patients,   the  
overall  response  was  up  to  72%  and  36%  of  the  patients  treated  with  TILs  achieved  
survival   longer   than   3   years   [140].   However,   this   approach   is   only   possible  when  
sufficient  amount  of  TILs  could  be  generated  from  the  same  patient.  To  overcome  this  
issue,  alternative  strategies  using  genetically  engineered  T  cells  were  developed.        
3.2.2  Creating  anti-­tumor  T  cells  through  genetic  modifications  
TCRs  that  recognize  tumor-­associated  antigens  (TAAs)  are  required  for  T  cells  to  lyse  
tumor  targets.  Thus,  genetic  engraftment  of  such  TCRs  (TCR-­T)  into  T  cells  enables  
their  specific  killing  against  tumor  cells  presenting  peptides  derived  from  TAAs  [141-­
143].  When  the  TAA-­specific  TCR-­T  cells  were  infused,   it  resulted  in  shrinkages  of  
tumor  burdens  in  patients  with  various  types  of  cancers  [141,  144-­146].  In  a  recently  
reported  clinical  trial,  T  cells  equipped  with  TCRs  specific  for  the  tumor  antigen  NY-­
ESO-­1  induced  tumor  regression  in  patients  with  metastatic  sarcoma  and  melanoma  
[147].  Even  though  TAA-­specific  CD8+  CTLs  are   important  for   the  cytolytic  effects,  
TCR-­engineered   CD4+   T   cells   also   play   indispensable   roles   when   infused  
simultaneously   [148,   149].   This   could   result   from   their   ability   to   produce   T   cell  
supporting  cytokines.  
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Alternatively,  T  cells  could  be  engineered  to  express  chimeric  antigen  receptors  (CAR-­
T).  In  these  structures,  the  extracellular  antigen  specificity  of  a  monoclonal  antibody  is  
coupled   to   the   intracellular   T   cell-­activating   signaling   domains   through   trans-­
membrane  spacer  molecules.  Since  the  initial  discovery,  several  improvements  have  
been   introduced,   mainly   through   fine-­tuning   the   contents   of   intracellular   signaling  
domains  [150,  151].  In  comparison  to  TCR-­Ts,  cytolytic  function  of  CAR-­Ts  does  not  
require   presence   of   the   MHC-­peptide   complexes   on   tumor   cells   and   T   cells   are  
sustained  by  multiple  activating  signals  coupled  to  the  CAR  complexes.  Therapeutic  
strategies   using   CAR-­Ts   targeting   CD19   (CD19-­CAR)   have   achieved   remarkable  
success  in  treating  refractory  B  cell  malignancies  [152-­155].  In  an  updated  report  with  
a   small   patient   cohort,   90%   (27   out   of   30)   of   relapsed   or   refractory   ALL   patients  
reached  complete  remission  after  CD19-­CAR  therapy  and  the  overall  survival  rate  was  
78%  at  6  months  [156].  In  solid  tumors  such  as  ovarian  cancer  [145,  157],  renal  cell  
carcinoma  [158-­160]  and  neuroblastoma  [161,  162],  CAR-­expressing  T  cells  were  less  
effective   in  controlling   tumor  progression.  This  could  be  explained  by   the   impaired  
persistence  and  survival  of  infused  T  cells  caused  by  hostile  environment  both  in  the  
blood   and   tumor   microenvironment.   Currently,   many   ongoing   clinical   trials   are  
exploring  the  therapeutic  potential  of  CAR-­expressing  T  cells  as  a  treatment  for  solid  
and  hematological  malignancies  [163].  
3.2.3  NK  cell  therapy  
In  contrast  to  T  cells,  lysis  of  tumor  cells  mediated  by  NK  cells  is  primarily  based  on  
the  mismatches  between  killer  cell  Ig-­like  receptors  (KIRs)  on  NK  cells  and  MHC  class  
I  molecules  on  target  cells.  This  important  feature  allows  recipients  to  accommodate  
NK  cells  derived  from  a  haploidentical  family  member.  In  addition,  NK  cells  express  
FcγR  on  the  surface  and  could  contribute  to  ADCC  effects  triggered  by  tumor-­binding  
antibodies.  Moreover,  death  receptors  on  NK  cells  could  induce  apoptosis  of  the  tumor  
cells  through  activating  caspase  pathways  [164].  Therefore,  highly-­activated  NK  cells  
are  suitable  for  treating  patients  with  cancers.  To  date,  most  promising  results  with  
adoptive  NK  cell  transfers  were  observed  in  patients  with  hematological  malignancies  
who   received   allo-­reactive   haploidentical  NK   cells   [165-­167].   Influenced   by   similar  
resilient  mechanisms  as  the  T  cells,  this  approach  is  yet  to  be  improved  in  controlling  
tumor  growth  in  patients  with  solid  tumors  [168-­170].    
3.2.4  DC-­based  therapy  
Dendritic   cells   are   professional   APCs   and   are   important   for   providing   the   ‘three  
signals’  during  T  cell  priming  (see  1.3).  Even  though  a  few  reports  acknowledged  their  
cytotoxic  functions  [171,  172],  DC  therapy  in  general  is  thought  to  mediate  tumor  killing  
through   enriching   tumor-­reactive   T   cells.   Since  most   of   the   treatment   procedures  
involve  generating  and   infusing  clinical  grade  DC  products   into  patients,   I  will  here  
categorize  it  as  one  of  the  cellular  therapies.    
In  principle,  DC-­based  therapeutics  require  generation  of  functional  DCs  followed  by  
decoration   with   TAAs.   Even   though   blood-­derived  monocytes   are  most   frequently  
used,  CD34+  hematopoietic  progenitor  cells  have  also  been  tested  as  precursors  for  
maturing  DCs  [173,  174].  To  introduce  TAAs,  various  methods,  including  direct  pulsing  
of   synthetic   peptides,   recombinant   proteins,   tumor   lysates   or   transfection-­based  
methods  have  been  implemented  [175].  Some  investigative  results  in  small  numbers  
of  cancer  patients  have  shown  promising  clinical  responses  [173,  174,  176-­178].  As  
the  first  FDA-­approved  cellular  therapy  in  2010,  Sipuleucel-­T  (Provenge)  was  one  of  
the  milestones  in  the  history  of  cancer  immunotherapy.  This  DC-­based  product  was  
used  to  treat  patients  with  refractory  prostate  cancer  and  could  prolong  overall  survival  
for  4.1  months   [179,  180].   In  general,  DC-­based   treatments  are  well-­tolerated  and  
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toxicity  is  minimal.  Recently,  the  clinical  values  of  naturally  occurring  DC  subsets,  such  
as  plasmacytoid  DCs  have  also  been  evaluated  [181,  182].  Even  though  infused  at  
low   numbers,   these   cells   were   able   to   generate   favorable   immune   responses   in  
patients  with  melanoma.  
3.2.5  Sustaining  infused  cells  in  vivo  
Current  protocols  implemented  for  adoptive  cell  therapy  require  rapid  activation  and  
expansion   of   patient-­derived   T   or  NK   cells   using   high-­dose   cytokines   or   agonistic  
antibodies.   The   resulted   cells   are   extremely   potent   in   killing   tumor   cells   in   vitro.  
Nevertheless,  a  marked  decrease  of  cell  numbers  was  observed  after  infusion  (from  
one  T  cell  in  580  PBMC  one  day  post  infusion  to  1  T  cell  per  35.400  PBMC  after  2  
weeks  [137]).  Some  argue  that  this  reflected  trafficking  of  the  infused  T  cells  to  various  
organs  and  tumor  sites.  But  others  proposed  that  it  was  mainly  due  to  in  vivo  apoptosis  
induced  by  cytokine  withdrawal  or  shortened  telomere  length  [183].    
In  comparison,  infused  at  as  low  as  1.5×105  cells  per  kilogram  body  weight,  CD19-­
CARs   proliferated   in   vivo   and   potently   controlled   tumor   progression   in   leukemia  
patients   [152,  184].  However,  when  similarly  designed  CAR-­T  cells  were   tested   in  
patients  with  solid  tumors,  infused  cells  rapidly  diminished  from  the  peripheral  blood  
and  failed  to  limit  tumor  growth  efficaciously  [161].  By  analyzing  intratumoral  CAR-­T  
cells  in  a  preclinical  animal  model,  recent  findings  suggested  that  inhibition  of  T  cell  
signaling,  rather   than   loss  of  CAR  expression  or  antigen-­carrying  tumor  cells  could  
contribute  to  this  result  [185].    
Thus,  sustaining  anti-­tumor  capacity  of  the  effector  cells  after   infusion  might  be  the  
key   to   a   successful   adoptive   cell   therapy.   This   goal   could   be   achieved   through   a  
number  of  approaches.  Firstly,  early  clinical  trials  using  anti-­viral  CD4+  CAR-­T  cells  
have  demonstrated  in  vivo  persistence  of  CAR-­expressing  T  cells  for  almost  a  decade  
[186].  This   implies  that  presence  of  antigen-­specific  central  memory  T  cells  (TCM)  
may  help  prolong  in  vivo  anti-­tumor  immunity  [187].  Given  the  central  role  of  IL-­15  in  
activating  memory  T  cells  and  NK  cells  in  cancer  patients  [188],  this  cytokine  holds  
substantial  promise  to  extend  the   in  vivo  life-­span  of  transferred  T  or  NK  cells.  This  
point  has  been  consolidated  in  experimental  animal  models,  where  tumor-­specific  T  
cells   persisted   in   vivo   when   activated   with   IL-­15,   possibly   through   recruiting   anti-­
oxidant  mechanisms  [189]  or  preventing  loss  of  telomere  [190].  Secondly,  it  is  rational  
to  use  combinational  approaches  to  sustain  T  cell  activities.  Results  of  a  phase  I  
clinical  trial  combining  DC  vaccines  with  TIL  therapy  in  a  small  number  of  melanoma  
patients  have  been  recently  released  [191].  The  combination  was  safe  and  generated  
promising   clinical   responses   and   the   updated   protocol   will   include   prior  
lymphodepletion   in   patients.   Based   on   similar   principles,   various   protective  
mechanisms  could  be  introduced  to  prevent  tumor-­induced  immune  suppression.  For  
example,  co-­transduction  of  IL-­12  into  CAR-­T  cells  improved  anti-­tumor  activity  in  mice  
by  potentiating  macrophage   functions   [192]  and  resisting  suppression  mediated  by  
Tregs  [193].  Lastly,  opportunities  for  improving  the  in  vivo  persistence  of  adoptively  
transferred  immune  effector  cells  may  underlie  novel  regulatory  mechanisms.  In  a  
recent  report,  pre-­activated  antigen-­specific  T  cells  were  infected  with  shRNA  libraries  
that  silenced  greater  than  1500  T  cell  regulatory  genes.  After  infusion,  T  cells  were  
retrieved  from  tumor  sites  and  spleens  and  compared  for  the  enrichment  of  shRNAs  
[194,  195].  This  approach  allowed  the  authors  to  identify  genes  that  were  important  
for  T  cell  functions  and  survival,  particularly  in  tumor  microenvironment.  These  results  
highlighted  that  loss  of  Ppp2r2d,  a  gene  without  previously  known  functions  in  T  cells,  
contributed   substantially   to   survival   and   proliferation   of   transferred   T   cells   in  
melanoma   tumors.   Therefore,   manipulating   these   novel   pathways   may   optimize  
longevity  of  transferred  effector  cells  in  patients  with  solid  tumors.     
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4.  THE  ‘DOUBLE  AGENTS’:  MYELOID  CELLS  IN  CANCERS  
4.1  BACKGROUD    
For   decades,   the   dynamic   interactions   between   chronic   inflammation   and   cancers  
have  been  carefully  dissected  [196].  It  has  been  well-­documented  that  non-­steroidal  
anti-­inflammatory  compounds,  such  as  aspirin,  prevent  occurrence  of  various  types  of  
human  cancers  [197].  Local  inflammation  in  tumor  tissues  is  represented  by  increased  
infiltration  of   leukocytes,  elevated   levels  of  cytokines  or  chemokines  and  abnormal  
angiogenesis.  Emerging  evidence  depicts  that  tumor-­driven  inflammation  also  has  a  
systemic  impact  on  the  peripheral  immune  system  and  tumor-­free  organs.  
In  cancer  patients,  circulating  monocytes  are   recruited   to   tumor   tissues  by  various  
chemokines,  such  as  CCL-­2,  and  skewed  into  ‘M2-­biased’  TAMs  [67,  198].  In  contrast  
to   their   ‘M1-­like’   counterparts,   TAMs   are   inefficient   in   producing   pro-­inflammatory  
factors   such  as   IL-­12  and  TNF-­α.   Instead,   they  hamper   tumor  eradication   through  
release  of  TGF-­β,  IL-­10,  PGE2  or  activation  of  regulatory  T  cells.  In  addition,  TAMs  
are  an  important  source  of  VEGF  and  PDGF,  which  support  abnormal  vasculature  in  
tumor   tissues.   Visualization   tools   revealed   that   TAMs   were   the   chaperones   for  
intravasation  of  tumor  cells  during  cancer  metastasis  [199].    
Recently,  the  role  of  myeloid-­derived  suppressor  cells  (MDSCs)  in  cancers  has  been  
highlighted.  Although  the  description  of  immature  ‘natural  suppressor’  cells  dated  back  
to  1970s,  it  was  not  until  2007  that  the  scientific  nomenclature  of  these  cells  could  be  
agreed  (Figure  1)  [200].  In  tumor-­bearing  mice,  MDSCs  are  defined  by  co-­expression  
of   CD11b   and   Gr1   and   could   be   further   divided   into   monocytic   (moMDSCs)   and  
granulocytic  (grMDSCs)  lineages  based  on  the  expression  levels  of  Ly6C  and  Ly6G  
[201].   In   cancer   patients,   phenotypic   definition   of   MDSCs   remains   challenging.  
Several   myeloid   markers   including   CD34,   CD33,   CD11b,   CD14,   HLA-­DR,   CD16,  
CD15  or  CD66b  have  been  suggested  as  individual  marker  or  in  combination  to  detect  
MDSCs  [202]  in  peripheral  blood  of  cancer  patients.  Thus,  the  general  consensus  for  
MDSC   definition   emphasizes   the   immature   phenotype   and   immune-­suppressive  
functions.  Due   to   the  complex   leukocyte  composition   in   tumor   tissues,   functions  of  
intratumoral  MDSCs  stay  controversial.  Previous  study  showed  that  MDSCs  isolated  
from  melanoma  tumor  tissues  lack  immune  suppressive  functions  in  comparison  to  
the  ones  in  the  blood  [203].  Conversely,   later  reports  demonstrated  that  MDSCs  in  
tumors  were  more  potent  in  exerting  suppression  on  T  cells  [204,  205].    
In   summary,   TAMs   and   MDSCs   are   both   heterogeneous   populations   that   bear  
overlapping  surface  markers  and  employ  similar  immune-­regulatory  mechanisms  in  
cancer  patients.  Since  the  phenotypic  signatures  and  suppressive  functions  of  TAMs  
[67,  198,  206]  and  MDSCs  [200,  202,  207]  have  been  extensively  reviewed  elsewhere,  
Figure  1,  Brief  history  of  myeloid-­derived  suppressor  cells  (MDSCs)  in  cancers.      
Modified  from:  Talmadge  and  Gabrilovich,  Nat.  Rev.  Cancer,  2013  Oct;;13(10):739-­52  
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I  will  instead  focus  on  the  clinical  implications  and  targeting  strategies  of  these  cells  in  
patients  with  cancers.  
  
4.2  MYELOID  CELLS  AS  BIOMARKERS  
As   mentioned   in   section   2.3,   immune   contexture   in   tumor   tissues   is   a   powerful  
prognostic  indicator  in  cancer  patients.  It  has  been  widely  reported  that  frequencies  of  
TAMs  predicted  survival  of  cancer  patients  [78-­81].  In  a  newly  proposed  evaluation  
system  (TMEM)  for  predicting  risk  for  metastasis  in  breast  cancer  patients,  infiltrating  
CD68+   cells   were   included   as   one   of   the   essential   criteria   [208].   However,   other  
studies  demonstrated  the  positive  prognostic  values  of  TAMs  [85,  209,  210].  These  
discrepancies  could  be  explained  by  the  highly  tissue-­dependent  and  versatile  nature  
of   macrophages,   particularly   in   tumor   tissues.   Thus,   it   is   becoming   increasingly  
attractive  to  explore  the  prognostic  potential  of  monocytic  and  granulocytic  MDSCs  in  
peripheral  blood  of  cancer  patients  (summarized  in  TABLE  1).  
Many  studies  have  reported  that  levels  of  moMDSCs  in  the  blood  correlated  well  with  
cancer  stages  and  predicted  survival   in  patients  with  melanoma   [211,  212],  breast  
[213,   214],   ovarian   [215],   colorectal   [216],   lung   [217]   and   various   types   of   other  
cancers   [218,  219].  This  was  recently  supported  by   the  observation   that   increased  
numbers  of  moMDSCs  reversely  associated  with  numbers  of  antigen-­specific  CD8+  
CTLs  in  melanoma  patients  [212,  220].    
It  is  widely  accepted  that  MDSCs  form  one  of  the  main  hurdles  for  sufficient  anti-­tumor  
immune  responses.  Presence  of  moMDSCs,  but  not  Tregs,  was  observed  at  higher  
levels   in  colorectal  cancer  patients  who  failed  to  respond  to  an  anti-­cancer  vaccine  
[221].  In  addition,  CD14+HLA-­DRlow/neg  moMDSCs  were  proposed  to  be  a  biomarker  
in   patients   who   received   a   multi-­epitope   peptide   vaccine   [222].   In   accordance,  
grMDSCs   diminished   from   the   peripheral   blood   in   patients   undergoing   ipilimumab  
treatment  [223]  and  frequencies  of  pre-­treatment  moMDSCs  appeared  at  higher  levels  
in   non-­responders   [220,   224].   However,   it   should   be   noted   that   blood-­derived  
moMDSCs  and  grMDSCs  have  distinct  properties  during  experimental  procedures  ex  
vivo.   While   moMDSCs   are   present   in   PBMCs   after   gradient   centrifugation,   high  
numbers   of   arginase-­producing   grMDSCs   could   only   be   co-­purified   from   blood   of  
cancer   patients   [225].   Since   cryopreservation   of   human   PBMC   could   drastically  
change  the  frequencies  and  suppressive  functions  of  grMDSCs  [226],  evaluation  of  
this  population  might  be  limited  if  only  frozen  materials  are  available.  
TABLE  1:  Prognostic  values  of  suppressive  myeloid  cells  in  cancer  patients  
Patients   Prognostic  values   Other  findings   Ref  
Melanoma  
Frequencies  of  moMDSCs  and  
Tregs,  but  not  the  grMDSCs,  
correlated  with  the  stage  and  poor  
prognosis  in  melanoma  patients  
Inflammatory  factors,  IL-­1β,  IFN-­
γ  and  CXCL10  in  the  sera  
correlated  with  the  Tregs  and  
MDSCs  
[211]  
Lower  moMDSCs  predicted  better  
responses  to  ipilimumab  
No  changes  of  moMDSCs  during  
ipilimumab  treatment  
[224]  
moMDSC  numbers  at  week  6  after  
ipilimumab  treatment  correlated  with  
overall  survival  
moMDSCs  were  inversely  
associated  with  CD8+  T  cell  
frequencies  
[220]  
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Frequencies  of  moMDSCs,  but  not  
Tregs,  predicted  poor  survival    
moMDSCs  reversely  correlated  
with  NY-­ESO-­1  and  Mart-­1  
specific  T  cells  
[212]  
Low  TAM  infiltration  predicted  better  
survival  in  uveal  melanoma  
TAMs  associated  with  higher  
density  of  microvasicles  
[227,  
228]  
Breast  cancer   CD68/CD4/CD8  in  tumor  tissues  
predicted  patient  survival  
Paclitaxel  treatment  increased  M-­
CSF  production  and  TAM  levels  
[229]  
TABLE  1  (continued) 
Patients   Prognostic  values   Other  findings   Ref  
   CD14+Arg+  cells  in  the  blood  
correlated  with  the  stage  of  the  
patients  
High  numbers  of  CD14+Arg+  cells  
were  detected  in  tumor  tissues  
and  draining  lymph  nodes  
[213]  
Circulating  MDSCs  correlated  with  
the  stages  of  the  disease  




CD68+  TAMs  were  used  to  predict  
metastasis  (TMEM)  
   [208]  
TAMs  were  an  independent  
prognostic  factor  for  survival  
TAMs  correlated  with  
angiogenesis  and  VEGF  in  
tumors  
[79]  
Higher  CD163+  and  CD68+  cells  
predicted  poor  survival    
Localization  in  tumor  stroma  but  
not  tumor  nest  was  important  
[230]  
Proliferative  TAMs  correlated  with  
higher  grade  tumors  
TAMs  did  not  correlate  with  
tumor  sizes  or  metastasis  
[81]  
Ovarian  Cancer   Blood  MDSCs  correlated  with  
primary  tumors  and  metastasis  
MDSCs  maintained  the  





Blood-­derived  MDSCs  correlated  
with  poor  prognosis  
Lineageneg  cells  in  bone  marrow  
were  the  suppressive  cells  
[216]  
Colorectal  
TAMs  increased  with  stages  and  
predicted  poor  survival  
Chemokine  expression,  
especially  CCL-­2  correlated  with  
stage  
[80]  
Non-­responders  to  an  anti-­cancer  
vaccine  had  high  blood  MDSCs  
Treg  did  not  predict  response   [221]  
Neuroblastoma  
Infiltration  of  inflammatory  myeloid  
cells  negatively  correlated  with  
survival  







High  moMDSCs  in  cancer  patients  
and  correlated  with  metastasis    





CD14+HLA-­DRlo/neg  MDSCs  strongly  
correlated  with  the  survival  of  
patients  after  cyclophosphamide  
and  IMA901  treatment  
Treg  numbers  before  treatment  





Common  myeloid  progenitors  
correlated  with  the  stage  of  cancers  
Myelopoiesis  skewed  towards  
granulocytic  lineage  
[218]  
Increased  MDSCs  and  Tregs  in  
cancer  patients  and  MDSCs  
predicted  poor  outcome  
MDSC  levels  correlated  with  





TAMs  were  associated  with  poor  
prognosis  
Frequencies  of  TAMs  predicted  
treatment  failure  rate  
[78]  
  
  17 
4.3  DRIVING  FORCES  FOR  SUPPRESSIVE  MYELOID  CELLS  
Tumor-­driven   inflammatory  mediators   are   the  most   frequently   cited  mechanism   to  
induce  myeloid   cells  with   suppressive   functions.  The  majority   of   published   studies  
employ   well-­designed   in   vitro   model   systems,   where   human   or   murine   immune  
(progenitor)   cells   are   exposed   to   tumor-­derived   factors.   These   findings   are   then  
validated  using  in  vivo  models  or  primary  immune  cells  sorted  from  cancer  patients.  
Even   though   most   research   articles   emphasize   the   importance   of   a   particular  
pathway,   it   is   likely   that  multiple   aspects   are   involved   in   regulating   the   diversified  
inflammatory  network.  Besides,   environmental   factors   such  as  hypoxia  and  acidity  
have  recently  been  revealed  to  shape  the  functions  of  myeloid  cells  (TABLE  2).    
4.3.1  Established  soluble  factors  
GM-­CSF  
Under  physiological  conditions,  GM-­CSF  is  one  of  the  driving  forces  for  myelopoiesis  
and  maturation  of  APCs.  Early  studies  showed  the  potent  anti-­tumor  effects  of  GM-­
CSF-­based  vaccines  in  preclinical  models  [232].  The  mechanisms  of  action  include  
enhanced  maturation  and  infiltration  of  ‘M1-­like’  macrophages  and  dendritic  cells.  In  
humans,  GM-­CSF  as   an   adjuvant   therapy  was   shown   to   be   clinically   favorable   in  
various   types   of   cancer   patients   [233-­235].   When   GM-­CSF   was   delivered   to  
melanoma   patients   by   an   oncolytic   vector   (OncoVex),   it   decreased   numbers   of  
MDSCs  as  well  as  Tregs  efficiently,  and  raised  antigen-­specific  T  cell  responses  [236].  
In   contrast,   one   clinical   study   using   GM-­CSF   as   an   adjuvant   therapy   increased  
moMDSCs  levels  in  melanoma  patients  and  these  cells  could  inhibit  lymphocytes  by  
producing  TGF-­β  [237].  These  controversial  findings  could  be  explained  by  the  dose-­
dependent  immune  modulatory  effects  of  GM-­CSF  in  vivo    [238].  In  an  animal  model,  
high-­dose  GM-­CSF,   but   not   intermediate   or   low-­doses,   hampered   efficient   tumor-­
reactive  immunity  by  inducing  MDSCs  [239].  This  was  supported  by  a  recent  clinical  
study,   where   low-­dose   GM-­CSF   adjuvant   treatment   did   not   increase   MDSCs   in  
pancreatic  cancer  patients  [240].  The  direct  link  between  tumor-­derived  GM-­CSF  and  
induction  of  suppressive  myeloid  cells  was  dissected  by  a  number  of  experimental  
models.  Together  with  other  factors  including  G-­CSF  or  IL-­6,  recombinant  GM-­CSF  
enabled  suppressive   functions  of  human  CD34+  hematopoietic  stem  cells   [218]  or  
primary  human  monocytes  [216,  241,  242].  In  a  Kras-­driven  pancreatic  tumor  model,  
neutralization  of  GM-­CSF  abolished  the  induction  of  suppressive  myeloid  cells  in  vivo  
[243].    
COX-­2/PGE2  
Prostaglandins   (PGs)   are   lipids   that   play   multifaceted   roles   during   inflammation,  
autoimmunity  and  cancer.  Cyclooxygenase-­2   (COX-­2)   is  an   inducible  enzyme   that  
regulates  the  production  of  PGE2.  It  is  often  over-­expressed  in  human  cancers  and  
indicated  to  be  a  parameter  associated  with  poor  prognosis  in  cancer  patients  [244].  
Even  though  PGE2  initially  was  thought  to  be  important  in  stimulating  dendritic  cells  
[245,  246],  recent  studies  have  revealed  its  alternative  role  in   inducing  suppressive  
functions   in   myeloid   cells.   In   human   ovarian   cancer   patients,   the   COX-­2/PGE2  
pathway  was  demonstrated  to  be  the  master  regulator   for  suppressive  functions  of  
MDSCs  via  a  positive  feedback  loop  [247].  Specifically,  PGE2  could  activate  a  panel  
of  suppressive  mechanisms   in  human  myeloid  cells,   including   IDO,  ARG1,  TGF-­β,  
PGE2   and   IL-­10   [247-­252].   Since   PGE2   is   a   strong   activator   for   the   JAK-­STAT  
signaling,  it  is  likely  that  this  is  the  main  pathway  controlling  these  events  [205,  253].  
Interleukin-­1  
IL-­1  is  another  widely  reported  factor  in  driving  the  induction  of  suppressive  myeloid  
cells  in  cancers.  In  a  recent  study,  IL-­1/IL-­1R  interaction  was  significantly  enhanced  
on  monocytes  isolated  from  patients  with  kidney  malignancies  and  drove  molecular  
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mechanisms  to  support  angiogenesis  and  cancer  invasion  [254].  In  preclinical  models,  
tumor-­derived  IL-­1β  could  augment  mRNA  expression  of  iNOS  and  ROS  in  myeloid  
cells,  and  could  therefore  be  a  potential  target  for  cancer  immunotherapy  [254-­257].  
TABLE  2:  Induction  mechanisms  of  suppressive  myeloid  cells  in  cancers  








TGF-­β   [237]  
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Various  tumors   HMGB-­1   IL-­10   [263]  
Colon  and  lymphoma  
(CT26  and  EL-­4)  
S100A9  
































Lung  cancer  (LLC)  
Hypoxia,  HIF-­1α   PD-­L1   [270]  
Lactic  acid,  HIF-­1α   ARG1  (mRNA)   [271]  









(antibody  or  silencing)  




Not  tested   [272]  
  
4.3.2  Emerging  inflammatory  factors  
Other  mediators  involved  in  inflammation  and  autoimmunity  also  take  part  in  cancer-­
induced   modulation   of   the   immune   system.   S100   proteins   are   conserved   among  
vertebrates  and  possess  calcium-­binding  properties   [273].  Among  all  21  members,  
S100A8  and  S100A9  are  by  far   the  most   investigated   in  suppressive  myeloid  cells  
[274].  These  two  proteins  can  form  heterodimers  (S100A8/9)  and  skew  myelopoiesis  
towards   a   suppressive   phenotype   by   binding   to   TLR4   and   RAGE   [262,   264].  
Accordingly,   higher   levels   of   soluble   S100A8/9   were   observed   in   blood   of   cancer  
patients  and  correlated  with  MDSC  frequencies  [275,  276].  Quinoline-­3-­carboxamide  
is  a  clinically  validated  compound  for  the  treatment  of  autoimmunity  and  inflammatory  
disorders.  A  recent  study  identified  that  it  directly  interacted  with  S100A9,  engaging  
both  Zn++  and  Ca++  [277].  Provided  that  S100A9  was  strongly  associated  with  poor  
clinical  outcome   in  prostate  cancer  patients   [278],   tasquinimod  has  been   tested   in  
randomized   clinical   trials   [279,   280]   and   is   currently   under   phase   III   clinical  
investigation  as  a  treatment  of  metastatic  prostate  cancers  (NCT01234311).  
Another   pro-­inflammatory   protein   that   interacts   with   TLR4   and   RAGE   is   HMGB-­1  
[281].  It  was  originally  recognized  for  its  regulatory  functions  on  DNA  conformation  but  
later  shown  to  be  released  by  macrophages  during  sepsis  [282,  283].  In  tumor-­bearing  
mice,  HMGB-­1  could  potentiate  the  production  of  IL-­10  via  NFκB  pathway  in  MDSCs  
and  directly  inhibit  functions  of  T  cells  [263].  In  addition,  post-­surgical  removal  of  colon  
cancer   tumor   masses   in   mice   resulted   in   elevated   production   of   HMGB-­1,   which  
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facilitated  the  recruitment  of  MDSCs  [284].  This  could  partially  contribute  to  cancer  
recurrence  after  surgery  in  patients  with  solid  tumors.  In  addition,  human  tumor  cells  
can  produce  HMGB-­1  in  an  autocrine  fashion  to  sustain  their  survival  and  proliferation  
[285],   potentially   through   modulating   mitochondrial   activities   [286].   Conversely,  
radiotherapy   or   irradiation   were   reported   to   induce   immunogenic   cell   death   by  
triggering  release  of  HMGB-­1  and  antigen  presentation  mediated  by  TLR4  on  DCs  
[287-­289].  These  findings  imply  the  dual  role  of  HMGB-­1  in  regulating  the  interplay  
between  tumor  cells  and  the  immune  system.  During  cancer  progression,  HMGB-­1  is  
released  as  a  mechanism  to  prevent  immune  surveillance.  When  tumor  masses  are  
assaulted  by  anti-­cancer  agents,  massive  production  of  HMGB-­1  in  combination  with  
other  pro-­inflammatory  factors  and  tumor-­associated  antigens  promote  activation  of  
APCs   and   T   cell   priming.   However,   retention   of   HMGB-­1   after   the   anti-­cancer  
treatments  recruits  immune  cells  with  tumor-­promoting  properties  and  contributes  to  a  
favorable  environment  for  cancer  recurrence.    
4.3.3  Hypoxic  and  metabolic  control  
Cancer   cells   are   highly   proliferative   and   can   avoid   programmed   cell   death.  
Consequently,   the   abnormal   metabolic   and   acidic   landscape   in   the   tumor   tissues  
creates  a  hostile  environment  for  anti-­tumor  immune  effectors.  In  normal  tissues,  HIF-­
1α  is  maintained  at   low  levels   in  myeloid  cells,  but  could  be  elevated  in  MDSCs  or  
TAMs   by   tumor-­induced   hypoxia   [265,   270,   290]   or   lactic   acid   [271,   291].   This  
activation   subsequently   results   in   enhanced   immune   expression   of   suppressive  
factors  such  as  arginase  and  immune  check-­point  PD-­L1  on  myeloid  cells.  Moreover,  
fast-­growing  tumor  cells   feature  high  concentrations  of  ATP  in  the  adjacent   tissues  
and  the  P2X7  receptor  on  myeloid  cells  could  capture  the  available  ATP  and  promote  
synthesis  of  arginase,  ROS  and  TGF-­β  [267].  In  line  with  these  findings,  differentiation  
of  MDSCs  was  shown  to  be  powered  by  mTOR/HIF-­1α-­regulated  glycolytic  activity  
[266].  Even   though   the  metabolic  alterations   in  cancer  cells  have  been  extensively  
discussed  [292],  it  is  only  recently  that  mTOR-­mediated  metabolic  control  was  shown  
Figure  2,  Functional  overview  of  interactions  between  MDSCs  and  tumors.      
Updated  from:  Mao,  Poschke  and  Kiessling,  J.  Intern.  Med.,  2014  Aug;;276(2):154-­70.  
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to   regulate   the   development   of   immune   cells   [293,   294].   Thus,   it   is   reasonable   to  
hypothesize  that  tumor-­induced  metabolic  rearrangements  may  have  a  great  impact  
on   the   immune   composition   in   cancer   patients.   In-­depth   understanding   of   these  
mechanisms   could   reveal   novel   targets   for   therapeutic   interventions   in   cancer  
treatment.  
  
4.3.4  The  ‘Jemaa  el-­Fnaa’  
The  activation  and  differentiation  of  suppressive  myeloid  cells  are  guarded  by  inter-­
connected  mechanistic  networks  (Figure  2).  Tumor-­induced  metabolic  and  oxidative  
changes  promote  myeloid  cells   to  acquire  suppressive  functions  through  a  HIF-­1α-­
mediated  machinery.  Meanwhile,  a  variety  of  tumor-­derived  factors,  such  as  GM-­CSF,  
PGE2,  IL-­1  and  IL-­6,  are  potent  inducers  for  JAK-­STAT  signaling  pathways,  which  in  
turn   activate   production   of   suppressive   factors   from  myeloid   cells.   Through   STAT  
signaling,  TNFα,  TGF-­β,  VEGF  [295],  PGE2  [296,  297]  or  the  hypoxic  environment  
[298]  also  enhance  the  production  of  pro-­inflammatory  HMGB-­1  or  S100  protein  family  
members.  On  the  other  hand,  suppressive  myeloid  cells  release  soluble  factors  such  
as   microRNAs,   ROS   or   various   inflammatory   mediators   and   deplete   essential  
metabolites   from   the   adjacent   areas.   This   collectively   reinforces   the   abnormal  
metabolic  and  oxidative  milieu,  which  facilitates  tumor  invasion  and  migration.  Even  
though   less  discussed   in   this   thesis,   interactions  among   immune  cells,  or  between  
immune  cells  and  endothelial  cells  or  fibroblasts,  amplify  the  cellular  complexity  in  the  
solid   tumor   microenvironment.   Thus,   instead   of   illustrating   this   network   as   many  
independent   one-­to-­one   dialogues,   it   resembles   my   experience   in   the   seemingly  
‘chaotic’  night  market  ‘Jemaa  el-­Fnaa’  in  Marrakesh  (Morocco).  Thousands  of  vendors  
and  customers  are  entering  and  exiting  the  market  and  simultaneously  interacting  with  
each  other.  Even  though  people  bargain  for  different  goods,  the  negotiation  methods  
and  tactics  are  largely  overlapping.    
4.4  TARGETING  SUPPRESSIVE  MYELOID  CELLS    
Suppressive  myeloid  cells  in  cancers  are  extremely  heterogeneous  and  characterized  
by   the   production   of   inhibitory   factors   but   lacking   immune-­stimulatory   potential.  
Because  they  often  share  surface  antigens  with  immune-­stimulatory  myeloid  cells,  it  
remains   challenging   to   specifically   target   these   cells   for   the   treatment   of   human  
cancers.   In   general,   existing   results   support   that   blockade   of   tumor-­induced  
inflammation  is  an  efficient  way  to  decrease  the  numbers  and  functions  of  suppressive  
myeloid  cells.  Standard  therapies,  such  as  surgery  or  radiation,  also  have  an  impact  
on  the  suppressive  myeloid  cells.  Even  though  certain  chemotherapeutics  have  been  
reported   to  ameliorate   the  expansion  of  suppressive  myeloid  cells,  other  cytostatic  
agents  have  demonstrated  a  promoting  role.  While  the  detailed  mechanisms  remain  
to  be  revealed,  recent  findings  suggest  that  targeted  therapy  or  immunotherapy  also  
reduce   suppressive   myeloid   cells   in   cancer   patients.   In   this   section,   I   have  
summarized  the  recently  reported  in  vivo  modulatory  effects  of  anti-­cancer  treatments  
on  suppressive  myeloid  cells,  especially  in  cancer  patients  (TABLE  3).  
4.4.1  Anti-­cancer  treatments  and  suppressive  myeloid  cells  
Standard  surgical  procedure  or  cytostatic  drugs  have  recently  demonstrated  their  role  
on  suppressive  myeloid  cells  in  cancer  patients.  Removal  of  tumor  burdens  by  surgery  
decreased  the  number  of  arginase-­producing  CD14+  cells  in  the  blood  of  breast  cancer  
patients   [213].   Chemotherapeutics,   such   as   gemcitabine,   capecitabine   [240],   or  
trabectedin  [299],  reduced  circulating  MDSCs  in  cancer  patients,  possibly  by  inducing  
selective   cell   death   through   the   caspase-­8   pathway   [299].   In   contrary,   treatments  
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using   doxorubicin,   cyclophosphamide   [214]   or   paclitaxel   [229]   have   resulted   in  
elevated   numbers   of   MDSCs   in   cancer   patients.   These   observations   were   in  
agreement  with   observations   in   tumor-­bearing  mice   [229,   299-­302].   Paradoxically,  
paclitaxel  [303-­305]  and  doxorubicin  [306]  could  reduce  accumulation  of  MDSCs  in  
preclinical  models.   This   could   be   explained   by   the   distinct   dosing   and   concurrent  
treatment  agents  used   in  humans  or  mice.  Although  not   yet   shown   in  humans,  5-­
fluorouracil  specifically  deleted  MDSCs  and  recovered  anti-­tumor  T  cell  responses  in  
mice  [307].  Furthermore,  low-­dose  irradiation  enabled  re-­activation  of  TAMs  to  an  anti-­
tumor  phenotype  that  was  featured  by  high  production  of  iNOS  and  potently  controlled  
tumor  growth  in  mice  [59].  
Novel   anti-­cancer   agents,   such   as   targeted   therapy   or   immunotherapy,   have   also  
shown   modulatory   roles   on   suppressive   myeloid   cells   in   patients   with   cancers.  
Vemurafinib,  an  inhibitor  targeting  a  BRAF  mutation  in  cancer  cells,  could  decrease  
moMDSCs  and  grMDSCs  in  peripheral  blood  of  melanoma  patients  [308].  However,  
it  remains  to  be  elucidated  whether  this  effect  was  directly  on  myeloid  cells  or  resulted  
from   rapid   tumor   shrinkage.   The   checkpoint   inhibitor   ipilumumab   also   induced   a  
marked  decrease  of  grMDSCs  in  the  blood  of  melanoma  patients  within  weeks  [223].  
Even  though  moMDSCs  frequencies  were  unchanged  during  the  antibody  therapy,  
pre-­treatment   levels   of  moMDSCs  were   associated  with   treatment   outcome   [224].  
Additionally,  adoptive  transfer  of  highly  activated  lymphocytes  reduced  MDSCs  in  the  
peripheral  blood  of  cancer  patients,  but  it  did  not  seem  to  predict  treatment  outcome  
in  these  patients  [309].  
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Renal  cell  
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Sunitinib  
Reduction  of  MDSCs  but  no  
correlation  to  tumor  burden  
[313]  
Reduced  immature  myeloid  




Reduction  of  MDSCs  and  
maturation  to  DCs  
[315,  
316]  




Decreased  MDSCs  and  
improved  antigen-­specific  
response  to  p53  
[317]  
Head  and  neck  
25-­hydroxyvitamin  
D3  
Decreased  CD34+  cells  in  the  




Significant  reduction  of  MDSCs  







Decrease  of  both  moMDSCs  
and  gr  MDSCs  in  the  blood  
[308]  
TABLE  3  (continued)  
Subject
s  







Reduced  numbers  of  Arginase-­
producing  grMDSCs,  but  no  
effects  on  moMDSCs  
[223]  
Denileukin  Diftitox    
(ONTAK)  
Induction  of  STAT-­3hi  












Induction  of  IDO  in  the  vaccine  
production  and  higher  
IDO+FoxP3+  cells  after  infusion  
[321]  






Repolarization  of  M2-­like  
macrophages  to  M1-­like;;  







Reduction  of  MDSCs  and  M2-­
like  macrophages,  significant  







PTX  induced  TAM  infiltration  
and  CSF-­1R  blocking  














+T  cell  transfer  
Depletion  of  MDSCs  and  







Blocking  CSF-­1R  improved  
anti-­tumor  immunity  mediated  
by  irradiation  by  depleting  








CSF-­1R  blockade  eliminated  
TAMs  and  moMDSCs  and  





T  cell  transfer  
+CSF-­1R  inhibitor  
(PLX3397)  
CSF-­1R  inhibition  improved  
efficacy  of  antigen-­specific  








Decreased  MDSCs  in  tumors;;  









TABLE  3  (continued)  
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[339]  
4.4.2  Alleviating  inflammation  
Given  that  chronic  inflammation  is  tightly  intertwined  with  cancer  progression,  agents  
with   anti-­inflammatory   properties   have   been   extensively   explored   in   patients   with  
cancer.  The  preventive  effects  of  COX-­2   inhibitors  on  cancer   incidence  have  been  
proven  in  large  numbers  of  patients  [197].  Besides  the  direct  limiting  effects  on  tumor  
cells,  modulation  of  suppressive  myeloid  cells  could  contribute  to  this  protection.  In  
experimental   settings,   genetic   ablation   of   tumor-­derived   COX-­2   [248]   or  
pharmacological   inhibition   of   COX-­1/2   [261,   334-­336]   efficiently   limited   the  
accumulation  of  suppressive  myeloid  cells   in   tumor-­bearing  animals  and   translated  
into  slower  tumor  growth   in  vivo.  However,  it  should  be  noted  that  COX-­2  inhibitors  
often  are  associated  with  cardiovascular  toxicity  [340].  A  recent  study  using  genomic  
analysis   of   COX-­2   deficient   mice   revealed   that   more   than   1000   genes   were  
differentially   expressed   in   the   kidney,   which   caused   dysregulation   of   nitric   oxide  
synthase  [341].  Therefore,   inhibitors  targeting  alternative  checkpoints  of  the  COX-­2  
pathway,  for  example  the  enzyme  mPGES-­1  [342],  should  be  explored.  
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Other  inflammatory  pathways  could  also  be  drugable  targets  for  blocking  suppressive  
myeloid  cells.  A  chemical  inhibitor,  tasquinimod,  specifically  binds  to  S100A9  and  was  
able  to  enhance  the  anti-­tumor  T  cell  response  in  animal  models  by  removing  MDSCs  
and  TAMs  [331].  It  is  currently  being  validated  in  a  phase  III  clinical  trial  in  metastatic  
prostate   cancer   patients   (NCT01234311).   Recently,   a   novel   ‘pepti-­body’  mediated  
potent  deletion  of  MDSCs  in  vivo  through  ligation  to  membrane-­bound  S100A9  [329].  
In  addition,  antagonizing   IL-­1R  signaling  could  block  TAM   functions  and  attenuate  
human  tumor  invasiveness  in  a  xenograft  model  [254].  
A   few   pharmacological   compounds   that   were   originally   designed   to   resolve  
physiological   inconveniences  have  demonstrated  anti-­tumor  capacity  by  re-­shaping  
tumor-­induced   inflammatory   landscape.   PDE-­5   inhibitors,   such   as   tadalafil   or  
sildenafil,   which   antagonize   cyclic   GMP   degradation   and   induce   release   of   NO,  
efficiently  controlled  tumor  growth  by  blunting  induction  of  suppressive  myeloid  cells  
in  head  and  neck  cancer  patients  [319]  and  pre-­clinical  models  [332,  333].  This  is  in  
line  with  another  study,  where  low-­dose  irradiation  potentiated  the  functions  of  iNOS-­
producing  myeloid  cells  [59].  On  the  other  hand,  an  inhibitor  blocking  iNOS  activity  
was  shown  to  be  effective  in  controlling  tumor  progression  by  attenuating  suppressive  
myeloid  cells  [269].  These  findings  may  reflect  the  dual  role  of  NO  production  during  
progression  and  treatment  of  solid  tumors.  
4.4.3  Restraining  induction  signals    
As  described  in  section  4.3,  the  precise  induction  pathway  for  suppressive  myeloid  
cells  is  still  unclear.  In  mice,  depletion  methods  using  antibodies  targeting  Gr-­1  are  
commonly  used  [329,  337].  However,  Gr-­1  is  not  expressed  in  humans  and  myeloid  
cells  quickly  recover  once  the  antibody  treatment   is  discontinued.  Thus,  restraining  
induction   signals   of   suppressive   myeloid   cells   is   clearly   more   beneficial   as   a  
therapeutic  option.  
Among  all   the   key  pathways,   antagonizing  M-­CSF   receptor   (CSF-­1R)   has   to   date  
demonstrated   the   most   profound   therapeutic   potential.   RG7155,   an   antibody  
developed   by   Roche   showed   consistent   effects   to   eliminate   TAMs   in   pre-­clinical  
murine  models,  non-­human  primates  and  cancer  patients  [310].  Data  from  a  phase  I  
clinical  trial  (NCT01494688)  in  patients  with  pigmented  villonodular  synovitis  (PVNS)  
disclosed  during  the  ASCO  annual  meeting  in  2014  (abstract  10504)  confirmed  the  
safety  of  the  treatment  and  9  out  of  10  patients  showed  progression-­free  survival  for  
up  to  17  months.  In  addition,  chemical  inhibitors  against  the  tyrosine  kinase  associated  
with   CSF-­1R   signaling,   such   as   BLZ945   (Novartis)   or   PLX3397   (Roche)   also  
demonstrated  encouraging  results  in  a  number  of  studies,  as  monotherapy  [301,  322]  
or   in   combination   with   radiotherapy   [324],   chemotherapy   [229,   301],   checkpoint  
inhibitors   [325],   adoptive   T   cell   transfer   [326]   or   anti-­angiogenic   antibody   [327].  
However,  in  a  phase  II  clinical  trial,  PLX3397  did  not  show  benefits  for  the  progression-­
free  survival  in  patients  with  recurrent  glioblastoma  (abstract  2023,  2014  ASCO  annual  
meeting).  Starting  from  January  in  2015,  the  first  clinical  trial  combining  the  anti-­PD-­1  
mAb   (Bristol-­Mayer  Squibb)   and   anti-­CSF-­1R  mAb   (Five  Prime)  was   initiated   in   6  
different  types  of  human  solid  tumors.    
It  is  worth  pointing  out  that  the  in  vivo  mechanisms  of  action  of  CSF-­1R  blockers  are  
yet   to   be   clarified.   In   a   few   pre-­clinical   tumor   models,   CSF-­1R   inhibition   as   a  
monotherapy   only   resulted   in   moderate   tumor   control,   despite   efficient   in   vivo  
depletion  of  TAMs  [301,  324,  326,  327].  In  contrast,  other  studies  [301,  322]  including  
study   IV   in   this   thesis   showed   potent   therapeutic   effects   of   CSF-­1R   blockade,  
potentially  through  re-­programming  myeloid  cells  in  the  tumors.  Of  note,  the  CSF-­1R  
blocking  antibody  depleted  TAMs  but  elevated  numbers  of  MDSCs  in  the  tumors  [310].  
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Besides   the   distinct   inflammatory   nature   of   each  murine   tumor  model,   the   in   vivo  
stability,   permeability   or   kinetics   of   the   compound   in   various   organs   may   greatly  
influence   the   treatment   outcome.   In   all   of   the   studies,   notably,   CSF-­1R   inhibition  
enabled   superior   synergistic   effects   in   the   respective   combinatorial   settings.   This  
confirms  that  suppressive  myeloid  cells  form  one  of  the  major  resistance  mechanisms  
towards  anti-­cancer  therapies  and  could  be  utilized  as  a  therapeutic  target.    
Based   on   the   similar   principle,   sunitinib   inhibits  multiple   receptor   tyrosine   kinases  
including  CSF-­1R,  CD117,   flt3,   and   could   also   block   the   induction   of   suppressive  
myeloid  cells.  In  patients  with  renal  cell  carcinoma,  sunitinib  efficiently  decreased  the  
numbers  of  immature  MDSCs  [313,  314]  and  enhanced  the  maturation  of  CD1c+  DCs  
[314].  In  addition,  sunitinib  could  potentially  elicit  similar  effects  in  lung  cancer  patients,  
as  indicated  in  an  in  vivo  murine  model  [328].  
4.4.4  Blocking  mobility  
Leukocyte  trafficking  is  guided  by  a  variety  of  chemokines  and  often  skewed  by  tumor-­
derived   factors.   In  malignant   conditions,   suppressive  myeloid  cells  are   recruited   in  
response  to  the  inflammatory  milieu  in  the  tumor  microenvironment.  Chemokine  (C-­C  
motif)  ligand  2  (CCL-­2),  released  by  tumors  is  key  to  the  infiltration  of  inflammatory  
myeloid  cells  [323].  A  therapeutic  antibody  (Calumab)  against  CCL-­2  has  been  tested  
in  a  phase  II  clinical  trial  in  metastatic  prostate  cancer  patients.  The  response  rate  was  
poor,  which  could  be  due  to  the  insufficient  neutralization  of  CCL-­2  in  patients  [312].  
To  overcome  this  problem,  CCR-­2,  the  receptor  for  CCL-­2  has  been  evaluated  as  an  
alternative   target.   Indeed,   blocking   CCR-­2   with   a   therapeutic   antibody   depleted  
MDSCs  from  tumor-­bearing  mice  and  synergized  with  adoptive  CD8+  T  cell  transfer  
[268].    
Figure  3,  Targeting  strategies  for  suppressive  myeloid  cells  in  cancers.  
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Another   important  migratory  molecule   is   CXCR-­2,   which   is   essential   for   recruiting  
myeloid  cells  during  inflammation-­driven  tumorigenesis  [343].  In  mice,  limiting  CXCR-­
2  functions  on  circulating  myeloid  cells  greatly  prevented  their   infiltration  into  tumor  
tissues  [339]  and  boosted  the  anti-­tumor  effects  of  anti-­PD-­1  blockade  [338].  
4.4.5  Reprogramming  activation  
Myeloid  cells  are  extremely  plastic  and  their  functions  are  substantially  influenced  by  
the  surrounding   factors.  Monocytes   isolated   from  blood  could  be  primed   in  vitro   to  
immune-­stimulatory  DCs   for   cancer   treatment  or   acquire   tolerogenic  properties   for  
combating  autoimmune  diseases.  Thus,  an  appealing  approach  for  cancer  treatment  
is  to  promote  the  re-­activation  of  suppressive  myeloid  cells  in  vivo.  To  some  extent,  
this  could  be  achieved  by  using  GM-­CSF,  which  enabled  the  maturation  of  MDSCs  to  
DCs  [236].  However,  it  should  be  carefully  calibrated  since  high-­dose  GM-­CSF  may  
support   the   expansion   of   MDSCs   in   vivo   [237].   Another   agent   that   has   potent  
reprogramming  function  of  suppressive  myeloid  cells  is  all-­trans-­retinoic  acid  (ATRA),  
which  is  structurally  similar  to  vitamin  A  and  is  used  to  treat  various  malignancies  [344].  
It  could  induce  a  DC-­like  phenotype  and  trigger  IL-­12  production  from  monocytes  in  
vitro   [345]   and   enhance   in   vivo   efficacy   of   cancer   vaccines   [346].  When   tested   in  
patients  with  renal  cell  carcinoma  or  lung  cancers,  MDSCs  were  diminished  from  the  
blood,  potentially  due  to  maturation  towards  functional  DCs  [315-­317]  mediated  by  the  
intra-­cellular  accumulation  of  glutathione   [347].  Moreover,  a  VEGF  blocker   (VEGF-­
trap)  [348]  has  also  promoted  the  maturation  of  DCs  in  cancer  patients,  but  it  did  not  
decrease  the  numbers  of  MDSCs  [311].  
4.4.6  To  Kill  two  birds  with  one  stone  
Suppressive   myeloid   cells   possess   multi-­faceted   functions   in   sustaining   cancer  
occurrence,   progression   and   metastasis   and   are   one   of   the   major   barriers   for  
successful  therapeutic  interventions  in  cancer  immunotherapy.  To  date,  tremendous  
efforts  have  been  invested  to  design  and  validate  pharmacological  compounds  that  
could  efficiently  target  these  mechanisms.  In  brief,  four  main  strategies,  including  1)  
blocking   the   induction,   2)   eliminating   the   presence,   3)   disarming   the   suppressive  
machinery  and  4)   facilitating  the  maturation,  have  been  proposed  (Figure  3).  From  
my  point  of   view,   it   is   risky   to  unselectively  neutralize   immune  modulatory   factors,  
since   many   of   them,   such   as   TGF-­β,   ROS,   PGE2   or   iNOS,   also   play   pivotal  
physiological  roles  in  humans.  Although  elimination  of  suppressive  myeloid  cells  has  
been  observed  in  patients  receiving  certain  anti-­cancer  agents,  the  mechanistic  details  
are  yet  to  be  clarified.  Therefore,  it  might  be  more  plausible  to  combine  approaches  
that  limit  tumor-­driven  induction  of  suppressive  myeloid  cells,  with  stimulatory  signals  
that   potentiate   their   functional   maturation.   Together,   this   may   not   only   remove  
immunosuppressive  barricades,  but  also  create  an  environment  that  is  favorable  for  
anti-­tumor  immunity,  both  in  the  periphery  and  in  the  tumor  microenvironment.  
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5.  IMMUNOTHERAPY:  WHERE  ARE  WE  HEADING?  
5.1  INTRODUCTION    
Combating   cancers   with   the   patient’s   own   immune   system   is   being   gradually  
acknowledged  as  an  attractive  therapeutic  option.  However,  a  range  of  hurdles  need  
to  be  overcome  for  achieving  curative  effects  in  patients  with  advanced  solid  tumors.  
Throughout  this  thesis,  I  have  highlighted  the  challenges  and  opportunities  posed  by  
myeloid  cells  with  immunosuppressive  properties.  However,  it  is  important  to  keep  in  
mind  that  this  is  only  one  of  the  many  mechanisms  that  tumor  cells  employ  to  prevent  
effective  immune  clearance.  We  also  cannot  ignore  that  different  cancer  types  may  
have  distinct  inflammatory  profiles,  leading  to  diversified  immune  landscapes.  Here,  I  
will  handpick  some  emerging  aspects  that  hold  promises  towards  improved  efficacy  
of  cancer  immunotherapy.  
5.2  COMBINATION  THERAPY:  Going  Beyond  the  Immunity  
5.2.1  Restoration  of  immune  functions  
The   unprecedented   success   of   cancer   immunotherapy   has   raised   excitements   in  
redesigning  current  cancer   treatment   regimens.  One  general  notion   is   to  pursue  a  
‘1+1>2’   scenario,   where   the   existing   therapeutics   that   trigger   anti-­tumor   immunity  
could  be  used  simultaneously  to  boost  the  effects  of  immunotherapy.        
Chemotherapeutics   and   radiation   therapy   are   known   to   modulate   immune   cell  
functions   including   the   myeloid   compartment   (section   4.4.1).   In   addition,   these  
treatments  are  thought  to  increase  the  permeability  of  solid  tumor  tissues  and  directly  
regulate  molecular  properties  of  cancer  cells,  making  them  more  sensitive  to  immune  
cell   mediated   lysis   [349].   Indeed,   synergistic   effects   could   be   achieved   when  
chemotherapy  or  radiation  was  combined  with  checkpoint  blocking  antibodies  [350-­
353].   Because   high-­dose   cytostatic   drugs   or   radiotherapy   could   limit   immune   cell  
functions   by   inducing   cell   death,   it   may   be   more   reasonable   to   implement   the  
‘metronomic   dosing’   [354]   of   the   agents   in   such   combinations.   This   notion   was  
supported  by  observations  in  preclinical  models,  where  fractionated  radiotherapy,  but  
not  a  single  high  dose,  boosted  the  anti-­tumor  effects  of  anti-­CTLA-­4  treatment  [355].  
These   synergistic   effects   of   fractionated   radiotherapy   with   checkpoint   blockade,  
particularly  for  the  PD-­1/PD-­L1  axis  could  be  explained  by  the  modulation  of  PD-­L1  
expression  on  tumor  cells  [350].  
Besides   suppressive   myeloid   cells,   many   players   in   the   cancer-­induced  
immunosuppressive  network  could  be  targeted  in  the  combinatorial  approaches  [356].  
For  example,  immunosuppressive  regulatory  T  cells  (Tregs)  may  cause  the  failure  of  
efficient  immune  surveillance  against  cancer  cells.  Depletion  of  Tregs  has  long  been  
investigated  as  a  potential  treatment  strategy  for  cancers  [357-­359].  The  anti-­tumor  
effects  of  anti-­CTLA-­4  mAb  in  mice  were  partially  due  to  removal  of  Tregs  by  ADCC.  
Moreover,   inhibitors   for   key   suppressive   mechanisms,   such   as   IDO,   have   also  
generated  additive  effects  as  part  of  combinational  approaches  in  preclinical  models  
[70,  71,  360].  
5.2.2  Correction  of  vasculature  
Initially,  anti-­angiogenic  therapy  was  believed  to  function  through  exhausting  nutrient  
supplies  for  cancer  cells  by  destroying  their  blood  supplies.  However,  later  evidence  
indicated   that   normalization   of   vascular   architecture   in   the   solid   tumor  
microenvironment  might  be  more  beneficial  [361],  possibly  due  to  the  repolarization  of  
M2-­like   macrophages   and   enhanced   destruction   through   infiltrating   immune   cells  
[362,  363].  VEGF  was  previously  shown  to  have  a  direct  role  on  T  cell  development  
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and  induced  exhaustion  of  CD8+  T  cells  in  tumors  [364-­366].  In  accordance,  blocking  
VEGF  potentiated  anti-­tumor  effects  of  DC  vaccines  [367]  and  adoptive  T  cell  therapy  
[368]   in   murine   models   and   supported   significantly   longer   patient   survival   when  
combined  with  chemotherapy  [369].  In  melanoma  patients,  anti-­angiogenic  antibody  
could  enhance  immune  cell  infiltration  after  ipilimumab  treatment  [370].  Similar  effects  
could  be  expected  when  VEGF  blockade  is  combined  with  inhibition  of  the  PD-­1/PD-­
L1  pathway.  In  a  recent  report,  tumor-­derived  VEGF  collaborated  with  IL-­10  and  PGE2  
to  induce  death  ligand  expression  on  endothelial  cells,  which  resulted  in  apoptosis  of  
infiltrating  CD8+  T   cells   [371].  Consequently,   combining  COX-­2   inhibitor  with   anti-­
VEGF  antibody  abolished  these  mechanisms  and  restored  anti-­tumor  immunity.  
5.2.3  Multi-­tasking  therapeutics  
Antibody  engineering  technology  allows  production  of  artificial  proteins  that  merge  two  
antigen  specificities.  Typically,  one  part  of  the  ‘bi-­specific’  antibody  recognizes  tumor-­
associated  surface  proteins,  while   the  other  part   could   trigger  T  cell   activation,   for  
example  through  CD3  signaling.  In  addition,  some  products  contain  the  Fc  domain,  
which  engages  ADCC  mediated  by  NK  cells  or  macrophages.  Therefore,  bi-­specific  
antibodies   are   extremely   potent   in   directing   tumor-­specific   killing   through   multiple  
cytotoxic  machineries  [372].  The  first  bi-­specific  antibody  approved  for  clinical  usage  
was   catumaxomab,  which   recognized  EpCAM  and   simultaneously   triggered  T   cell  
activation  through  CD3  signaling  [373].  Based  on  similar  concepts,  a  collection  of  bi-­
specific  antibodies  were  designed  and  investigated  for  cancer  treatments  [372].    
However,  severe  adverse  events  induced  by  bi-­specific  antibodies  hamper  the  clinical  
application  in  a  wider  range  of  cancer  patients.  This  is  partially  due  to  the  anti-­CD3  
fragment,  which  elicits  excessive  T  cell  activation   in   vivo.  Decreased  dosing  could  
alleviate  toxicity  but  also  jeopardize  the  anti-­tumor  efficacy.  In  a  preclinical  model,  this  
issue   could  be   compensated  by   combining   low-­dose  anti-­GD2  bi-­specific   antibody  
with  DC  vaccines  [374].  Alternatively,  such  toxicity  might  be  attenuated  if  the  anti-­CD3  
domain   is  replaced  by   fragments   that   liberate   tumor-­reactive  T  cells   from  inhibitory  
pathways,  such  as  PD-­1  or  PD-­L1  signaling.  This  approach  may  facilitate  an  antigen-­
directed  activation  of  T  cells   in   the  proximity   to   tumor  cells,  which  could  be   further  
supported   by   effector   cells   engaged   through   ADCC.   For   cancer   types   that   lack  
common   antigens,   multiple   immune   checkpoint   blocking   fragments,   or   fragments  
potentiating  reprogramming  of  suppressive  myeloid  cells,  such  as  anti-­CSF-­1R,  could  
be  collaborated.    
Another  novel  concept  that  is  currently  under  clinical  development  is  the  production  of  
high-­affinity,   antigen-­specific   monoclonal   TCRs.   These   proteins   recognize   defined  
epitopes   of   tumor-­associated   antigens   presented   by  MHC   class   I   molecules.   The  
linked  anti-­CD3  ScFv  could  attract  and  activate  T  cells  to  conduct  specific  lysis  of  the  
tumor  cells  [375,  376].  In  comparison  to  monoclonal  antibodies,  this  approach  could  
target   antigens   that   are   derived   intra-­cellularly.   It   also   circumvents   the   laborious  
preparation  procedure  of  TCR-­transduced  T  cells  required  for  adoptive  T  cell  therapy.    
Besides  engineered  biological  products,  some  naturally  existing  proteins  could  also  
play  multi-­faceted  roles  in  directing  immune  responses.  CD80  provides  co-­stimulation  
through  CD28  during  T  cell  priming,  which  is  often  interrupted  by  immune  checkpoint  
molecules  in  the  tumor  microenvironment.  Thus,  the  soluble  form  of  CD80  protein  is  
likely  to  restore  T  cell  functions  by  blocking  immune  checkpoint  interactions,  as  well  
as   offering   additional   co-­stimulatory   signals.   Indeed,   a   CD80-­Fc   fusion   protein  
improved  functions  of  human  and  murine  T  cells,  even  more  pronounced  than  blocking  
antibodies   against   the   PD-­1/PD-­L1   axis   [377,   378].   This   indicates   that   previously  
unidentified   receptors   are   involved   in   CD80   ligation.   However,   CD80   has   been  
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reported  to  be  expressed  at  high  levels  on  the  surface  of  MDSCs  in  cancer  patients  
[253]   and   tumor-­bearing   mice   [379],   and   has   been   proposed   to   be   one   of   the  
suppressive   mechanisms   against   T   cells.   Of   note,   the   CD80-­Fc   fusion   protein  
activated,   rather   than   inhibited   human   and   murine   T   cell   functions   in   vitro.   This  
suggests   that  membrane-­bound  CD80  may  have  distinct  biological   functions  to   the  
soluble  proteins.  Even  though  the  in  vivo  efficacy  remains  to  be  seen,  the  CD80-­Fc  
fusion  protein  may  amplify  anti-­tumor  capacity  via  elimination  of  Tregs  or  PD-­L1+  cells  
by  ADCC.    
5.2.4  Risks  analysis  
Novel  concepts  of  combination  therapy  are  accompanied  with  previously  unrecorded  
concerns   and   clinical   complications.   For   example,   concurrently   administrating  
blocking   antibodies   for   CTLA-­4   and   PD-­1   amplified   the   autoimmune   toxicity  
associated  with  either  antibody  alone  [109].  In  another  case,  devastating  liver  toxicity  
was   reported   when   inhibition   of   BRAF   oncogene   mutation   was   combined   with  
ipilimumab  [380].  These  cases  restate  the  necessity  of  conducting  risk  assessments  
while   new   combinatorial   approaches   are   being   clinically   investigated,   even   if   the  
individual  treatments  have  been  approved  separately  by  the  regulatory  agencies.    
5.3  TECHNOLOGICAL  ADVANCES  
Currently,  the  enthusiasm  towards  cancer  immunotherapy  is  immense.  However,  we  
still  cannot  underestimate  challenges  from  immune  suppression  and  the  potential  risk  
in  using  immune-­stimulatory  agents  that  elicit  immune  responses  unselectively.  Thus,  
we  need   to  be  able   to   improve  exclusively   tumor-­specific   immunity  and  accurately  
manipulate  immunosuppressive  mechanisms.  To  reach  this  goal,  we  need  technical  
advances   that   enable   comprehensive   analysis   of   the   human   immune   system   and  
precise  modulation  of  immune  cell  subsets.    
5.3.1  Biomaterials  and  immunotherapy  
Advances   in  biomedical  material  research  hold  great  promises   in   improving  clinical  
efficacy   and   safety   of   cancer   immunotherapeutics.   Encapsulation   of   biological  
products,   for  example  cytokines  or  antibodies,   into  engineered  nanoscale  vehicles,  
could  optimize  their  in  vivo  stability  and  pharmacokinetics.  This  is  particularly  attractive  
for  agents  that  have  severe  systemic  adverse  effects.  In  a  proof-­of-­principle  study,  a  
nanoporous  material  supported  gradual  release  of  the  anti-­CTLA-­4  mAb  in  vivo  and  
the  anti-­tumor  effects  were  improved  [381].  It  is  also  possible  to  equip  nanoparticles  
with   multiple   immune   stimulatory   properties,   creating   controllable   doses   of  
personalized  therapeutic  ‘cocktails’.  For  example,  nanoparticles  conjugated  with  co-­
stimulatory  anti-­CD137  mAb  and  IL-­2  induced  profound  anti-­tumor  effects  in  tumor-­
bearing  mice  [382].  When  decorated  with  ‘anchors’  recognizing  surface  molecules  on  
tumor  cells,  it  is  possible  for  the  systemically  injected  nanoparticles  to  locally  deliver  
agents  that  otherwise  induce  systemic  adverse  events.  Similarly,  nanoparticles  could  
be  used  to  maintain  in  vivo  activity  of  adoptively  transferred  anti-­tumor  effector  cells  
by  specific  delivery  of  immune  activating  factors  [383,  384].  Moreover,  it  is  possible  to  
specifically  and  more  efficiently  target  or  reprogram  suppressive  myeloid  cells  using  
these  approaches.  
Some  naturally  occurring  nanoscale  vesicles  could  also  be  used  as  novel  therapeutic  
approaches.  Exosomes  are  released  as  ‘messengers’  from  biologically  functional  cells  
and   encapsulate   contents   that   could   conduct   versatile   properties   on   the   immune  
system.  Tumor-­derived  exosomes  have  been  shown  to  induce  suppressive  myeloid  
cells  by  delivering  factors  such  as  PGE2,  TGF-­β  [385]  or  membrane-­bound  Hsp72  
[386].  On  the  other  hand,  exosomes  shed  from  DCs  carry  co-­stimulatory  molecules  
 32 
and   are   able   to   stimulate   antigen-­specific   immune   responses.   Therefore,   it   has  
economically   attractive   to   utilize   these   exosome   as   the   DC-­surrogates   in   treating  
cancer  patients    [387].  Several  studies  have  proven  that  exosomes  derived  from  DCs  
were  immune  stimulatory  and  potentiated   in  vivo  protective  effects  in  tumor-­bearing  
mice  [388,  389],  through  activation  of  T  and  B  cells  [390,  391].    
Currently,  the  majority  of  cancer  vaccines  inject  peptides,  proteins  or  DNA  plasmids  
that  contain  potential  T  cell  epitopes  directly  into  patients.  In  most  cases,  this  approach  
elicits   protective   immune   responses   against   the   given   antigen(s),   but   has  modest  
therapeutic   effects   against   established   tumors   [392].   Thus,   encapsulating   tumor-­
associated   antigens   into   biomedical   materials   may   be   advantageous   for   cancer  
vaccine   approaches   by   prolonging   in   vivo   exposure,   specific   delivery   to   APCs   or  
enabling  co-­delivery  of  adjuvants   [393].  A  number  of  studies   focused  on  delivering  
antigens   and   adjuvants   to   residing   DCs   in   lymph   nodes   [394,   395].   An   emerging  
perspective  is  to  program  dendritic  cells  in  situ  by  implanting  nano-­scaffolds  containing  
tumor-­associated  antigens  [396].  A  recent  update  from  the  same  group  utilized  nano-­
scaffolds  with  self-­assembling  properties  after  implantation.  This  allowed  formation  of  
a  3D  mesoporous  structure,  where  immune  cells  from  the  host  animal  could  be  primed  
against   tumor-­associated   antigens   [397].   This   resulted   in   controlled   and   durable  
release   of   immune   activating   contents   and   recruited   substantial   tumor-­rejecting  
humoral  and  cellular  immune  mechanisms.    
5.3.2  Mega-­analysis  of  immune  responses  
The  immunological  response  to  cancer  occurrence  or  therapeutic   interventions   is  a  
fine-­tuned  network  of  numerous  parallel  events.  Contents  in  the  extracellular  matrix,  
cell   surface   proteins   or   intracellular   signaling   pathways   collaboratively   govern   the  
success   of   treatment   strategies.   Therefore,   a   comprehensive   overview   of   these  
components  and  the  subsequent  signaling  cascades  has  substantial  prognostic  and  
therapeutic  implications  in  guiding  the  development  of  cancer  immunotherapy.  
Development   of  multi-­color   flow   cytometry   was   a  milestone   achievement   and   this  
method  is  currently  widely  used  for  analyzing  immunological  profile  in  cancer  patients.  
Using  fluorochrome-­conjugated  antibodies,  a  sophisticatedly  designed  flow  cytometry  
platform   allows   detection   of   10   to   15   proteins   simultaneously.   When   appropriate  
lineage   markers   are   included,   the   results   reflect   cellular   properties   of   a   defined  
immune  cell  subset  at  a  given  time.  However,  immune  cell  populations  are  extremely  
heterogeneous  and  analysis  of  large  numbers  of  functional  pathways  are  also  required  
to   accurately   dissect   major   disease-­   or   treatment-­related   cellular   alternations.  
Therefore,   technological   advances   empowering   massive   data-­recording   and  
processing  are  in  great  demand.    
Cytometry   by   Time-­of-­Flight   (CyToF)   is   a   powerful   cell   detection   method   with  
significantly  improved  protein  detection  capacity.  Instead  of  fluorophores,  antibodies  
are  labeled  with  element   isotopes  and  recorded  by  subsequent  mass  spectrometry  
[398,   399].   This   approach   potentiates   measurement   of   up   to   (theoretically)   100  
parameters  at  the  same  time  and  circumvents  the  compensation  step,  a  procedure  
that  is  required  for  correcting  spectral  overlaps  among  different  fluorochromes.  In  one  
of  the  first  studies  using  this  technology,  34  parameters  were  characterized  by  CyToF,  
in   order   to   depict   the   hematopoietic   hierarchy   and   response   to   pharmacological  
inhibitors  [400].  A  later  study  analyzed  the  virus-­specific  CD8+  T  cells  and  identified  
previously   less   appreciated   complexity   within   the   population   [401].   Application   of  
CyToF  technology  has  also  been  extended  for  imaging  tumor  tissues.  Recently,  32  
parameters  were  measured  simultaneously   in  breast  cancer   tumor   tissues  and   the  
extremely  heterogeneous  sub-­populations   in   the   tumor  microenvironment  could  be  
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delineated  [402].  Although  these  platforms  are  not  currently  applicable  to  fulfill  routine  
clinical  demands,  they  hold  great  potential  to  reveal  vital  information  towards  in-­depth  
understanding  of  the  anti-­tumor  immunity.    
Given   the   heterogeneity   of   myeloid   compartment,   CyToF   platform   may   offer   a  
powerful   tool   to   scrutinize   the   regulatory   network   during   the   development   and  
activation  of  suppressive  myeloid  cells.  In  addition,  anti-­tumor  T  cell  responses  after  
immunotherapy  could  be  better  illustrated  not  only  in  the  peripheral  blood,  but  also  in  
solid   tumor   tissues.   This   may   allow   us   to   uncover   novel   therapeutic   targets   and  
prognostic   markers   that   facilitate   our   understanding   on   tumor-­induced   immune  
suppression  and  guide  the  development  of  novel  treatment  strategies.    
5.3.3  Precise  genome  editing    
  The  CRISPR-­Cas9  system  is  a  natural  defensive  mechanism  utilized  by  bacteria  and  
archaea,   in  order   to  prevent   incorporation  of   foreign  DNAs  into  their  own  genomes  
[403].  Guided  by  a  short  RNA  sequence,  the  Cas9  endonuclease  could  use  molecular  
scissors  to  cut  on  a  precise  point  and  disable  the  functions  of  invading  DNAs.  With  
appropriate  engineering,  the  CRISPR-­Cas9  system  could  be  used  as  a  tool  to  modify  
genome  on   the   desired   locations   accurately   [404].   It   has   shown  promising   clinical  
implications,  particularly  for  correcting  genetic  flaws  in  human  stem  cells  [405,  406].  
For   the   treatment  of  cancers,  some  studies  encourage  direct   injection  of  CRISPR-­
Cas9   in   vivo,   which   targets   and   corrects   cancer-­driven   mutations.   However,   this  
approach  should  be  carefully  evaluated  since  the  injected  agents  could  be  neutralized  
by  the  host’s  immune  system,  thus  may  have  low  penetration  into  the  tumor  tissues.    
Seattle-­based  corporation  Dendreon,  known  to  develop  the   first  FDA-­approved  DC  
vaccine  approach,  claimed  bankruptcy  at  the  end  of  2014.  The  high  treatment  cost  
and  the  modest  clinical  benefits  might  be  the  main  hurdles  for  Provenge,  their  prostate  
cancer   vaccine,   to   be   commercially   appealing   for   a   large   number   of   patients.   It  
definitely   does   not   discredit   the   clinical   efficacy   of   DC-­based   therapies.   Rather   it  
reflected  the  challenges  of  implementing  cell-­based  therapies  in  the  real-­life  scenario.  
Alternatively,  RNA-­guided  genome  editing  may  be  utilized   to   improve   immune  cell  
functions   against   human   cancers.   After   acquisition   of   the   GMP   facilities   from  
Dendreon,  pharmaceutical  giant  Novartis  is  leading  the  way  to  evaluate  CD19-­CAR  T  
cells  for  the  treatment  of  hematological  malignances  in  a  phase  II  clinical  trial.  It  is  now  
becoming   clear   that   the   CRISPR-­Cas9   technology   will   be   incorporated   into   this  
treatment.  Even  though  the  detailed  applications  are  not  yet  disclosed,  a  few  potential  
modifications  could  be  speculated.  Firstly,   the  current   treatment   strategy  of  CD19-­
CARs   requires   isolation  and   transduction  of   autologous  T   cells   for   each   individual  
patient.   It   is   a   labor-­intensive   procedure   that   requires   tremendous   amounts   of  
dedication  and  expertise.  Therefore,   if   the  HLA  class   I  molecules  and   the   intrinsic  
TCRs  could  be  silenced  from  the  CAR-­transduced  T  cells,  it  will  be  possible  to  prepare  
universal  CD19-­CAR  T  cell   products   that   are  not   destroyed  by   the  host’s   immune  
system  or  perturb  graft-­versus-­host  reactions.  This  could  be  a  key  step  to  implement  
the   treatment   in  a  more  standardized  and  cost-­effective  manner.  Secondly,  certain  
molecules   hampering   in   vivo   functions   of   the   adoptively   transferred   T   cells,   for  
example  PD-­1  or  CTLA-­4,  could  be  removed  using  the  CRISPR-­Cas9  system.  This  
step   restricts   the   functional   enhancement   to   tumor-­reactive   T   cells,   avoiding  
unselective   activation   of   T   cells   often   induced   by   checkpoint   blocking   antibodies.  
Furthermore,  upon  establishment,  the  genome-­editing  tools  could  modify  genes  that  
are   crucial   for   the   in   vivo   durability   of   the   adoptively   transferred   T   cells,   such   as  
Ppp2r2d.  This  might  be  less  critical  for  the  success  of  CD19-­CAR  T  cells  but  could  
have  substantial  implications  for  adoptive  cell  therapies  against  solid  tumors.  
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5.4  INTERDISCIPLINARY  FRAMEWORK  FOR  CANCER  IMMUNOTHERAPY  
In  the  modern  day  cancer  research,  the  rigid  boundaries  among  research  disciplines  
are  diminishing.  Although  studies  of  cancer  genetics  are  still  the  mainstay  for  many  
cancer  types,  associations  between  genomic  instability  and  inflammation  have  been  
elucidated.   Powerful   next   generation   sequencing   platforms   are   now   employed   to  
pinpoint  mutations  that  may  contain  neo-­epitopes  that  guide  potent  T  cell  responses.  
Moreover,  development  of  high  through-­put  analytical  approaches,  such  as  CyToF,  
requires   specialists   in   bioinformatics   for   reliable   data   interpretation   and   validation.  
Rapid  advances  in  biotechnology  and  molecular  biology  have  broadened  the  genetic  
editing   arsenal   with   superior   accuracy   and   specificity.   Nano-­technology   inventions  
promise  greater  future  potency  and  safety  for  today’s  medicine.  Although  these  are  
just  very  few  examples,   it   is  evident  to  me  that  tumor  immunologists  can  no  longer  
dissect  complicated  research  questions  and  develop  effective  anti-­cancer  therapies  
without   key   contributions   from   other   research   disciplines.   The   interdisciplinary  
framework   that   marries   a   wide   range   of   expertise   and   know-­how   today,   is   the  
foundation  for  an  improved  patient  survival  tomorrow.  
6.  SUMMARY  OF  THE  MAJOR  FINDINGS  
The  central  aim  of  this  thesis  is  to  elucidate  how  tumor-­derived  factors  could  induce  
suppressive  functions  from  healthy  myeloid  cells.  The  detailed  interactions  between  
patient-­derived  MDSCs  and  T  cells,  NK  cells  and  DCs  were  analyzed  in  study  I,  II  and  
III,   respectively.  Study   IV  extended   this  evaluation   to   the  myelopoiesis  process  of  
human  hematopoietic  stem  cells  and  suppressive  myeloid  cells  were  explored  as  a  
therapeutic  target  in  mice  developing  aggressive  spontaneous  tumors.      
6.1  Study  I:  TUMOR-­DRIVEN  INDUCTION  OF  MDSC  IS  MEDIATED  BY  COX-­
2/PGE2  
Motivation  
Human  melanoma   is  believed   to  be  one  of   the   cancer   types   that   is   responsive   to  
immunotherapy  due  to  its  high  mutation  rates  associated  with  UV-­induced  damages.  
We  and  many  other  groups  have  noted  the  accumulation  of  suppressive  MDSCs  in  
the  peripheral  blood  of  melanoma  patients  and  these  cells  may  hamper  effective  anti-­
tumor  immunity.  However,  the  mechanisms  of  their  induction  remain  unclear.  Thus,  
we  sought  to  analyze  the  precise  pathways  that  regulate  the  induction  of  MDSCs.  
Experimental  Design  
To  dissect  the  detailed  mechanisms,  I  established  a  co-­culture  model,  where  primary  
human  monocytes   from  healthy  donors  were  exposed   to  early-­passage  melanoma  
tumor   cell   lines   expanded   from   fresh   patient   biopsies.   Next,   the   tumor-­educated  
monocytes   were   retrieved   from   cultures   and   their   phenotype   and   T   cell   inhibitory  
functions  were  evaluated.  A  variety  of  pharmacological  inhibitors  were  added  during  
the  co-­culture,  to  analyze  the  key  regulators  driving  tumor-­induced  alterations.  
To  assure  that  our  in  vitro  findings  were  clinically  relevant,  we  purified  monocytes  from  
blood  of  patients  with  advanced  melanoma.  These  cells  were  subsequently  added  to  
autologous   T   cells   and   the   suppressive   mechanisms   were   compared   to   those  
obtained  from  in  vitro  induced  MDSC-­like  cells.  
Main  Findings  
After  in  vitro  co-­culture  with  early-­passage  melanoma  tumor  cells,  healthy  monocytes  
acquired   a   phenotype   resembling   CD14+HLA-­DRlow/-­   moMDSCs   in   melanoma  
patients.  In  addition,  MDSC-­like  cells  and  patient-­derived  monocytes  potently  inhibited  
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T  cell  effector   functions.  Mechanistically,  COX-­2/PGE2  pathway  was   involved  both  
during  the  induction  of  MDSC-­like  cells  and  inhibition  of  T  cells  because  a  selective  
COX-­2   inhibitor   (Celecoxib)   or   a   PGE2   neutralizing   antibody   could   restore   T   cell  
functions.  Finally,  adding  synthetic  PGE2  to  monocytes  increased  their  ability  to  inhibit  
T  cells.  
Outlook  of  the  Study  
One  major  limitation  of  the  co-­culture  model  was  that  it  did  not  reflect  the  impact  of  
tumor-­derived   factors   on   myelopoiesis,   which   may   directly   contribute   to   the  
immobilization   of   progenitor   cells   and   production   of   immature  myeloid   cells   in   the  
peripheral  organs.  In  addition,  we  utilized  a  panel  of  inhibitors,  in  order  to  dissect  the  
main   channels   that   led   to   the   induction   of   MDSCs.   However,   selection   of   these  
inhibitors   were   based   on   previously   reported   pathways.   Thus,   a   comprehensive  
comparison  between  control  monocytes  and  MDSC-­like  cells  by  genomic  or  proteomic  
screening  may  identify  novel  pathways  that  are  involved  in  this  process.  
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6.2  Study  II:  MDSCS  SUPPRESS  NK  CELLS  THROUGH  TGF-­β  
Motivation  
NK  cells  play  an  important  role  in  modulating  tumor  growth  and  metastasis  and  could  
be   used   as   a   therapeutic   approach   to   treat   human   cancers.  Although   interactions  
between  MDSCs  and  T  cells  have  been  frequently  reported,  the  effect  of  MDSCs  on  
NK   cells   is   controversial.   Therefore,   we   aimed   to   analyze   the   precise   interplay  
between  these  two  immune  cell  types  in  patients  with  melanoma.  
Experimental  Design  
We  utilized  PGE2-­treated  human  monocytes  and  autologous  NK  cells  as  an  in  vitro  
model   to   study   their   interactions.   To   validate   the   mechanisms,   we   performed  
experiments  using  moMDSCs  and  NK  cells   isolated  from  blood  of  advanced  stage  
melanoma  patients.  Further,  we  inoculated  control  or  COX-­2-­silenced  murine  tumors  
in   mice   and   compared   the   frequencies   of   MDSCs   by   flow   cytometry   and   in   vivo  
cytolytic  capacity  of  NK  cells  by  live  imaging  in  tumor-­bearing  mice.    
Main  Findings  
We   demonstrated   that   PGE2   could   trigger   the   production   of   soluble   TGF-­β   from  
healthy  monocytes  through  the  PGE2  receptors  EP2  and  EP4.  This  was  the  major  NK  
suppressive  mechanism  utilized  by  PGE2-­treated  monocytes  and  moMDSCs   from  
melanoma  patients.  In  vivo,  COX-­2  silencing  resulted  in  a  marked  decrease  of  MDSCs  
in  the  spleens  and  a  concurrent  increase  of  cytotoxicity  mediated  by  NK  cells  in  the  
tumor-­bearing  mice.    
Relevance  of  the  Study  
Currently,  the  impact  of  cancer-­driven  MDSCs  on  NK  cells  in  tumor-­bearing  mice  is  
controversial.  MDSCs  were  reported  to  suppress  NK  cells  [407]  through  membrane-­
bound  TGF-­β  [408].  However,  another  report  indicated  the  stimulatory  role  of  MDSCs  
on  NK  cells   in  a  NKG2D-­dependent  manner   [409].   In  melanoma  patients,   interplay  
between  MDSCs  and  NK  cells,  particularly  the  molecular  mechanisms,  are  much  less  
investigated.    
Our  results  demonstrate  how  tumor-­derived  PGE2  could  drive  the  induction  of  MDSCs  
that  suppress  NK  cells  in  patients  with  advanced  melanoma.  It  revealed  a  previously  
unknown  connection  between  PGE2  and  the  release  of  TGF-­β  from  human  primary  
monocytes.  COX-­2   inhibitors  may  have  off-­target  effects  or  a  direct   impact  on   the  
suppressive  functions  of  MDSCs.  Thus,  our  approach  using  tumor  cells  with  genetic  
ablation  of  COX-­2   in   vivo   allowed  specific   analysis   of   the   impact   of   tumor-­derived  
COX-­2/PGE2  on  the  induction  of  MDSCs  and  inhibition  on  NK  cells.  In  summary,  this  
study  expanded  our  current  understanding  on  the  multi-­faceted  role  of  tumor-­derived  
PGE2,   which   recruited   MDSCs   to   suppress   NK   cells   in   cancer   patients.   Thus,  
targeting   COX-­2/PGE2   pathway   could   synergize   with   the   anti-­tumor   effects   of  
adoptive  NK  cell  therapy.  
6.3  Study  III:  MDSCS  IMPAIR  THE  MATURATION  OF  DENDRITIC  CELLS  
Motivation  
Currently,  DC-­based   therapy  often   relies  on  maturation  of  monocytes  purified   from  
blood  of  cancer  patients.  Inevitably,  moMDSCs,  with  known  ability  to  suppress  various  
types  of   immune   cells,  will   be   present   during   the  process.  Thus,   it   is   important   to  
evaluate  the  role  of  moMDSCs  and  how  their  presence  could  influence  quality  of  the  
resulting  DC  vaccines.  
Experimental  Design  
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The   clinical   materials   were   obtained   from   stage   IV  melanoma   patients   who   were  
enrolled  in  a  phase  I  clinical  study  (MAT01)  [191],  where  DC  vaccines  were  combined  
with  adoptive  T  cell  transfer.  Patients  underwent  leukapheresis  and  monocytes  and  
lymphocytes  were  enriched  in  different  cell  fractions  by  elutriation.  Monocytic  MDSCs  
were  isolated  based  on  the  low  surface  expression  of  HLA-­DR  and  HLA-­DR+  cells  
from  the  same  donor  were  used  as  controls.  Next,  moMDSCs  were  mixed  with  HLA-­
DR+   cells   at   escalating   ratios,   to   evaluate   their   influence   on   the   quality   of   DC  
maturation.  
Main  Findings  
We  found  that   the  presence  of  moMDSCs  did  not  alter   the  yield  of  DCs  but  had  a  
negative  impact  on  DC  quality.  In  detail,  high  frequency  of  moMDSCs  at  the  beginning  
of  DC  maturation  procedure  blocked  the  up-­regulation  of  activation  markers  and  co-­
stimulatory  signals  on  DCs  and   impaired   the  ability  of  DCs   to   take  up  antigens,   to  
migrate  and  stimulate  T  cell  functions.    
Relevance  of  the  Study  
This  study  is  part  of  an  ongoing  clinical  trial,  where  patients  received  cellular  therapy  
combining   DC   vaccines   and   adoptive   T   cell   therapy.   Our   data   provided   critical  
information   regarding   the   impact   of  moMDSCs  on   the  overall   quality   of  DC-­based  
vaccines.   Even   though   moMDSCs   could   be   matured   upon   stimulation,   their  
performance  was  sub-­optimal  in  comparison  to  the  HLA-­DR+  cells.  In  addition,  their  
presence  had  a  ‘by-­stander’  effect,  which  negatively  affected  the  maturation  of  HLA-­
DR+  cells.  Based  on  these  results,  there  is  an  ongoing  research  project  in  our  group,  
where  optimized  protocols  for  DC  maturation  are  being  tested.  
6.4  Study  IV:  CSF-­1R  INHIBITION  AS  A  POTENT  APPROACH  TO  BOOST  ANTI-­
TUMOR  IMMUNITY  
Motivation  
Neuroblastoma  is  one  of  the  most  common  solid  cancer  type  among  infants.  Despite  
the  aggressive  therapies,  high-­risk  patients  still  suffer  from  poor  survival  and  there  is  
a   great   need   for   novel   treatments.   Inflammation-­driven   expansion   of   suppressive  
myeloid  cells  play  pivotal  roles  in  neuroblastoma-­mediated  immune  suppression  and  
these   cells   could   independently   predict   worse   clinical   outcome   in   neuroblastoma  
patients  [231].  Thus,  it  might  be  a  suitable  cancer  type  for  therapeutic  interventions  by  
targeting  these  cells.  
As  mentioned  in  earlier  sections,  it  is  challenging  to  target  suppressive  myeloid  cells  
specifically  due  to  their  heterogeneous  nature.  CSF-­1R  signaling  is  important  for  the  
survival  and  development  of  myeloid  cells  and  we  sought  to  inhibit  this  pathway  to  limit  
the  induction  of  suppressive  myeloid  cells.  
Experimental  Design  
To  evaluate  the  immune  system  in  neuroblastoma  patients,  in  particular  the  myeloid  
compartment,  we  analyzed  publically  available  expression  datasets  by  searching  the  
R2  database  (see  6.5.3).  In  order  to  elucidate  the  impact  of  neuroblastoma-­derived  
factors  on  the  differentiation  of  myeloid  cells,  we  established  3  in  vitro  models  (Figure  
4),  where  human  CD34+  hematopoietic  stem  cells,  primary  monocytes  and  murine  
bone  marrow  cells  were  cultured  in  the  presence  of  neuroblastoma  tumor-­conditioned  
medium   (TCM).   In   addition,   inhibitors   of  CSF-­1R   signaling  were   added   into   these  
cultures  and  the  subsequent  phenotypic  and  functional  changes  of  myeloid  cells  were  
evaluated.  To  test  the  therapeutic  potential  of  CSF-­1R  inhibition  in  vivo,  we  employed  
a  mouse  model,  in  which  human  oncogene  MYCN  drives  the  development  of  highly  
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aggressive   spontaneous   neuroblastoma   from   adrenal   medullas.   Mice   bearing  
palpable  abdominal  tumors  were  treated  with  a  selective  CSF-­1R  inhibitor,  BLZ945,  
or  in  combination  with  checkpoint  blocking  antibodies  against  the  PD-­1/PD-­L1  axis.  





In  comparison  to  benign  neurofibroma  tissues,  we  found  that  neuroblastoma  tissues  
expressed  higher  levels  of  M-­CSF  and  CSF-­1R.  Indeed,  both  M-­CSF  and  CSF-­1R+  
myeloid   cells   predicted   poor   survival   in   patients   without   prior   treatments.   These  
findings  were  validated  using   in  vitro  culture  models,  where  CSF-­1R  signaling  was  
proven   to  modulate  myelopoiesis   of   human   CD34+   hematopoietic   stem   cells   and  
murine  bone  marrow  cells  and  enabled  suppressive   functions   from  primary  human  
monocytes.  When  mice  were  treated  with  CSF-­1R  inhibitor  in  the  therapeutic  setting,  
the  progression  of  highly  aggressive  tumors  was  efficiently  controlled.  This  was  mainly  
due   to   the   specific   effects   on   suppressive   myeloid   cells   in   vivo.   To   our   surprise,  
checkpoint  blocking  antibodies  against  PD-­1/PD-­L1  had  no  impact  on  the  suppressive  
myeloid  cells  and   failed   to  control   tumor  growth   in   the  TH-­MYCN  mice.  Combining  
CSF-­1R   inhibition  with  checkpoint   inhibitors  enabled  striking  anti-­tumor  effects   that  
were  superior  to  either  treatment  alone.    
Relevance  of  the  Study  
It   is   well-­appreciated   that   tumor-­derived   factors   facilitate   the   engraftment   of  
hematopoietic  stem  cells  in  the  periphery,  leading  to  splenic  production  of  immature  
myeloid  cells  in  mice  [410].  However,  these  effects  were  less  understood  in  humans.  
In  this  study,  we  comprehensively  elucidated  the  impact  of  CSF-­1R  signaling  on  early  
differentiation  and  local  activation  of  suppressive  myeloid  cells  in  humans  and  mice.  
These   models   could   be   potentially   applicable   to   dissect   myeloid   cell   functions   in  
various  types  of  solid  tumors.    
According  to  published  findings  using  the  TH-­MYCN  murine  model  of  high-­risk  human  
neuroblastoma,  it  is  extremely  difficult  to  achieve  meaningful  therapeutic  effects  due  
to  the  known  short  treatment  window  and  rapid  disease  progression  once  the  tumors  
are  established  and  palpable  [411].  Although  targeting  suppressive  myeloid  cells  have  
long  been  considered  as  an  attractive  option   to   improve  cancer   immunotherapy   in  
other   cancer   types,   our   study   is   the   first   documentation   of   the   in   vivo   synergistic  
potency   between   a   small   molecule   CSF-­1R   inhibitor   and   checkpoint   blocking  
antibodies  in  controlling  aggressive  progression  of  spontaneous  tumors.  In  fact,  the  
relative  success  in  novel  treatment  of  these  animals  resulted  in  prolonged  survival  but  
none  of  the  animals  was  cured  or  even  showed  shrinkage  of  tumors  contrasting  our  
current   results   [412,   413].   Therefore,   the   study   has   a   unique   strength   in   that   the  
combination  therapy  resulted  in  outstanding  curative  effects  in  75%  of  the  treated  mice  
and  prevented  the  aggressive  progression  of  large  tumors  among  the  remaining  ones.  
Given   that   the   therapeutic  efficacy  of  PD-­1  blockade  and   the  prognostic   values  of  
suppressive  myeloid  cells  are  being  tested  in  various  human  cancers,  this  study  may  
have  a  broad  implication  for  the  therapy  of  human  cancers.  
6.5  TECHNICAL  DETAILS    
6.5.1  In  vitro  models  to  study  suppressive  myeloid  cells  in  humans  and  mice  
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To  investigate  the  induction  of  suppressive  myeloid  cells,  three  in  vitro  models  were  
established,   where   human   primary   monocytes,   cord   blood-­derived   CD34+  
hematopoietic   progenitor   cells   or   murine   bone   marrow   cells   were   cultured   in   the  
presence  of  tumor-­derived  factors  (Figure  4).    
The  model  co-­culturing  primary  human  monocytes  with  tumor  cell  lines  reflected  how  
differentiated  myeloid  cells  could  gain  suppressive   functions  under   the   influence  of  
tumor-­derived   factors.   To   maximize   the   physiological   relevance,   freshly   isolated  
melanoma   tumor   cells   were   expanded   from   lymph   node  metastases   of   advanced  
stage  melanoma  patients  and  utilized  at  early  passages  (<7  passages).    
The  monocyte-­tumor  co-­cultures  have  limited  power  to  reflect  the  influence  of  tumor-­
derived   factors   on   myelopoiesis,   which   may   result   in   accumulation   of   immature  
suppressive  myeloid  cells  in  the  periphery.  To  overcome  this  issue,  I  established  an  
in  vitro  model,  where  CD34+  hematopoietic  stem  cells  purified  from  cord  blood  were  
matured   in   the   presence   of   tumor-­conditioned   medium.   This   allows   us   to   more  
accurately  dissect  the  impact  of  tumor-­derived  factors  on  the  early  differentiation  of  
the  myeloid  compartment.  
Based  on  several  previously  published  reports  [243,  414],  we  utilized  an  additional  in  
vitro  model,  where  murine  bone  marrow  cells  were  cultured  in  the  presence  of  tumor-­
conditioned  medium.  This  essential  model  offered  a  time  effective  method  that  allowed  
us  to  select  myeloid-­modulating  compounds  before  testing  in  the  in  vivo  models.    
Collectively,   these   three   independent   approaches   enabled   us   to   gain   in-­depth  
understanding  of  the  induction  and  functions  of  suppressive  myeloid  cells  in  cancer  
patients   and   tumor-­bearing   animals.   More   importantly,   we   were   able   to   select  
compounds   in   a   cost-­   and   time-­efficient   manner   that   may   have   a   greater   in   vivo  
impact.  
6.5.2  The  TH-­MYCN  neuroblastoma  murine  model  
Figure  4,  In  vitro  models  to  study  tumor-­induced  differentiation  of  suppressive  
myeloid  cells.    
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The   transgenic   murine   model   that   spontaneously  
develops  neuroblastoma  was  established  by  Weiss  
et   al.   in   1997   [415].   In   this   model,   human   proto-­
oncogene   MYCN      is   controlled   by   tyrosine  
hydroxylase   promotor   (TH-­MYCN),   which   is   active  
during   early   development   of   migrating   cells   in   the  
neural  crest  [416].  Thus,  TH-­MYCN  transgenic  mice  
express  high  levels  of  human  MYCN  protein  in  the  
adrenal  gland  and  paraspinal  ganglia,  which  results  
in   induction  of  spontaneous  neuroblastoma   tumors  
that  resemble  the  aggressive  growth  pattern  of  high-­
risk   neuroblastoma   patients.      Following   the   tumor  
incidence  and  treatment  window  suggested  by  a  previous  study  [417],  mice  received  
3  abdominal  palpations  per  week  and  spontaneously  arising  tumors  were  harvested  
10  days  after  detection.  As  shown  in  Figure  5,  large  spontaneous  tumors  arise  from  
the  adrenal  gland  in  these  mice  and  situate  between  kidneys  in  the  abdominal  cavity.  
The   non-­treated   control   mice   on   average   developed   tumors   weighing   1.5   grams,  
approximately  7.5  %  of  the  body  mass  (20  grams).  
6.5.3  The  R2  database  
The  ‘R2:  microarray  analysis  and  visualization  platform  (http://r2.amc.nl)’   is  a  public  
database  containing  enormous  amounts  of  valuable  expression  datasets  extracted  
from  various  types  of  healthy  tissues,  tumor  tissues  or  cell  lines.  The  purpose  of  this  
database   is   to   create   a   user-­friendly   environment   for   biologists   to   test   relevant  
hypotheses  using  existing  datasets.  In  certain  patient  datasets,  additional  pathological  
information  or  clinical  outcome  of   the  patient  cohorts  are  also  available.  Thus,   this  
platform   provides   an   extremely   efficient   tool   for   researchers   who   lack   immediate  
access  to  clinical  samples.  In  study  IV  of  this  thesis,  we  have  retrieved  key  clinical  
information  supporting   the   relevance  of   targeting  CSF-­1R+  myeloid  cells   in  human  
neuroblastoma  datasets.  However,  given  that  genomic  information  cannot  completely  
reflect  dynamic  changes  of  the  biological  network,  we  have  extensively  validated  the  
results  by  protein  detection  methods  or  assays  enabling  functional  evaluations  at  the  
cellular  level  or  in  the  in  vivo  environment.  
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encouraged  my  creativity.  
Isabel,  you  introduced  me  to  some  of  the  most  important  techniques  I  know  today  and  your  
presence  catalyzed  my  smooth  integration  into  the  projects  and  the  group.  You  have  nicely  
demonstrated  the  key  features  of  a  successful  doctoral  training  and  I  continuously  benefit  from  
your  sharp  comments  and  constructive  criticisms.  
Karl-­Erik  and  Ingegerd  Hellström,  your  mentoring  in  Seattle  initiated  my  scientific  adventure  
in   the   field   of   tumor   immunology.  Even   though  we   no   longer  work   together,   I   have   never  
stopped  receiving  guidance  and  encouragements  from  you.  I  am  one  of  the  many  who  have  
been  inspired  by  your  life-­long  passion  and  dedication  towards  research.  
Key  contributors  to  study  II  and  IV  
Dhifaf,   from   the   very   first   day,   you   impressed   me   with   your   tremendous   motivation   on  
research.   But   what   really   inspired   me,   is   your   maturity   and   persistence   under   difficult  
circumstances.  These  qualities  have  made  our  collaboration  efficient  and  highly  enjoyable.  
Nina,  you  are  one  of  the  most  dedicated  and  well-­trained  scientists  and  I  truly  appreciate  your  
high   level   of   research   integrity   and   scientific   credentials.   Your   endless   efforts   in   our  
collaboration  have  contributed  some  of  the  most  exciting  results  in  this  thesis  and  pushed  the  
project  to  a  completely  different  level.  
The  tumor  immunology  society  on  the  CCK  floor  01  
My  personal  development  has  been  stimulated  by  the  unique  scientific  ‘micro-­environment’  on  
the  first  floor.  Every  previous  and  present  member  of  the  Kiessling/Lundqvist  group  has  in  her  
or  his  own  way  influenced  my  work.  It  is  indeed  a  luxury  for  me  to  not  only  maintain  positive  
work  relations,  but  also  establish  personal  connections  with  many  of  my  colleagues.  
Maarten,  it  has  really  been  a  pleasure  to  have  you  as  one  of  my  fellow  PhD  students  from  the  
beginning.  I  am  always  amazed  by  your  enthusiasm  on  research  and  the  amounts  of  effort  
you  are  willing  to  invest  on  helping  others.  I  look  forward  to  your  success  after  summer!  Erik  
(broshan!),  your  positive  attitude  and  great  sense  of  humor  have  in  many  occasions  rescued  
me  from  devastating  situations.  Yago,  we  travelled  most  often  to   international  conferences  
and  you  are  the  expert  to  upgrade  days  from  interesting  to  AWESOME.  Tom,  you  impressed  
me  during  your   internship  and  I  hope  your  talents   in  research  will  come  across  your  bright  
medical  career  in  the  future.  Tanja,  thanks  for  sharing  with  me  your  expertise  on  T  cells  
and  also  the  fascinating  stories  from  the  north.  Veronika,  thanks  for  being  well-­organized  
and  energetic  as  the  next  dedicated  FACS  guru.  Kristina,  I  am  sure  you  will  produce  super  
NK  cells  in  no  time.  Helena,  I  always  enjoyed  the  time  when  we  could  exchange  thoughts  over  
a  cup  of  coffee.  Jeroen,  I  appreciate  that  you  have  broadened  my  view  with  your  knowledge  
and  Yuya,  I  am  sure  you  will  help  a  lot  of  patients  in  Japan.  Maria  and  Ulrika,  your  essential  
daily  contributions  are  critical  for  the  function  of  the  entire  group.  Finally,  thanks  to  the  good  
time  with  the  recent  group  members  Bettina,  Kevin,  and  Iva.  
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Previous  postdoctoral  fellows  Dimi,  Riki,  Alvaro,  Behavesh,  Simona,  Chiara  and  Takashi,  
you  all  have  substantially  influenced  my  research,  especially  in  the  beginning.  My  work  was  
also  supported  by  the  excellent  previous  group  members,  Maxi-­Lu,  Jochen,  Özcan,  Nicole,  
Christina,  Madhura,  Giusy,  Sara,  Renee,  Mamud,  Franziska  and  Aline.  
Collaborators  and  friends  
Special  thanks  to  the  neuroblastoma  experts,  Per,  John  Inge,  Lena-­Maria,  Linda,  Jelena,  
Anna,  Malin,  Cecilia  and  Lotta,  for  the  support  and  interest  on  our  collaboration.  Ola,  Laia,  
Vincent,  Shuo  and  Carl,  thank  you  for  your  patience  in  introducing  me  to  the  mysterious  RNA  
world  and  being  so  great  hosts  at  the  SciLife  pub.  Xiaonan  and  Stig,  it  was  fantastic  to  get  
acquainted  with   the  powerful  seahorse  platform.   Inclusion  of   the  precious  patient  materials  
was   made   possible   by   the   efficient   clinical   partnership   with   Johan,   Giuseppe,   Maria  
Wolodarski,  Roger,  Suzanne  and  Jana.    
Majken,  Tatjana,  Jeanette,  Emma  and  Charlotte,  myeloid  cells  are  the  way  to  go!  Thanks  
to  the  extremely  friendly  floor  members  Tina,  Torbjörn,  Anders,  Du  Juan,  Cecilia,  Nathalie,  
Linnea,  Andreas,  Lars  and  congratulations  to  Nikolas  for  the  recent  promotion  as  a  father!  
In  addition,   the  Thursday   floor  Fika  has  always  been  enjoyable  with  Elle,  Elizabeth,  Lars  
Adamson,  Amir,  Mohammed,  Barbro,  Ingrid,  Ann,  Salam,  Kia,  Eva-­Lena  and  Fariba.  
My  time  at  CCK  has  been  made  very  interactive  by  the  pub  crew,  Sara,  Sophia,  Nathalie,  
Ran,  and  the  OPUS  editorial  members,  Emma  (the  boss),  Matheus  and  Iryna.  Mahdi,  thanks  
for  coaching  me  on  how  to  get  into  shape  in  the  gym.  I  appreciate  the  friendship  established  
in  Stockholm  with张烨，刘超，烁哥，沁子姐，毕然，王宇，Alireza,  Pinar,  Mindy,  Patricia,  
Mikael,  Gianluca,  Xinsong,  Caroline,  Lidi,  Mei  and  Qiang.    
Also  for  the  advice  and  help  received  from  Lars  Holmgren,  Angelo,  Dan,  and  Erika.  And  
thanks  for  the  tricks  and  tips  on  fixing  the  FACS  machine  from  Juan.  
Lastly,  to  my  external  mentor  Karin  Aasa,  I  highly  value  your  career  advice  that  help  me  to  
develop  my  professional  qualifications.    
External  collaborators  
Stanley,   it  was  my  huge  pleasure  to  host  you  twice  here   in  Stockholm  and   it   intrigued  me  
every  time  we  discussed  the  work.  Barbara  and  Andre,  your  excellent  contributions  in  study  
II   are  always  highly  appreciated.  Mike,   I   appreciate   your   insightful   comments  and  a  great  
sense  of  humor.  
I  also  thank  Novartis  for  providing  the  BLZ945  compound  for  the  study  IV  and  the  scientific  
discussions  with  Novartis  researchers  Jim  and  Marion.  
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Nina,  you  are  a  person  with  such  a  gentle  heart  and  you  sincerely  care  about  people  around  
you.  It  calms  me  down  every  time  I  look  into  your  beautiful  eyes.  I  can’t  describe  how  lucky  I  
have  been  to  have  your  support  during  my  PhD.  Maria,  you  welcomed  me  every  time  with  
open  arms  and  delicious  wines.  Your  courage  and  dedication  always  inspired  me.  Katrin  and  
Christoph,   and   your   adorable   daughters  Hannah   and  Mathilda,   thank   you   for   the   great  
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hospitality  and  you  make  my  every  visit  memorable.  I  am  sure  you  will  enjoy  the  summer  here!  
Tilo  and  Ruth,  and  your  beautiful  children  Inga  and  Jan,  it  has  always  been  a  blast  to  meet  
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Wallenberg’s   Foundation,   the   Karolinska-­sponsored   Center   for   Immune   Modulatory  
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